预约演示
更新于：2026-02-28
Cefazolin Sodium
头孢唑林钠
更新于：2026-02-28
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1973-10-04), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H24N8NaO9S3 |
InChIKeyCQCPLXCVNXNUCK-HGUWTHONSA-N |
CAS号115850-11-8 |
关联
172
项与 头孢唑林钠 相关的临床试验NCT07267650
Analgesic Efficacy of iPACK Block Versus Periarticular Infiltration as an Adjunct to Femoral Triangle Block in Total Knee Arthroplasty: A Prospective, Randomized, Double-Blind, Controlled Trial
This study aims to compare two different multimodal analgesic techniques for pain management after total knee arthroplasty (TKA). The primary purpose is to determine if a combination of two specific nerve blocks administered by an anesthesiologist (Femoral Triangle Block + iPACK block) results in superior pain control compared to a combination of a nerve block and a local infiltration administered by the surgeon (FTB + Periarticular Infiltration [PAI]).
The hypothesis is that the FTB + iPACK combination will lead to a significant reduction in Numeric Rating Scale (NRS) pain scores with movement at 24 hours postoperatively.
This will be a prospective, randomized, double-blind, parallel-group, single-center study involving patients scheduled for primary unilateral TKA. Participants will be randomly assigned to one of two groups. All patients, clinicians (anesthesiologists and surgeon), and outcome assessors will be blinded to the group allocation using a double-dummy technique.
The hypothesis is that the FTB + iPACK combination will lead to a significant reduction in Numeric Rating Scale (NRS) pain scores with movement at 24 hours postoperatively.
This will be a prospective, randomized, double-blind, parallel-group, single-center study involving patients scheduled for primary unilateral TKA. Participants will be randomly assigned to one of two groups. All patients, clinicians (anesthesiologists and surgeon), and outcome assessors will be blinded to the group allocation using a double-dummy technique.
开始日期2026-01-01 |
申办/合作机构- |
CTR20255246
以注射用头孢唑林钠静脉输注作为对照，比较注射用BJ009（皮下注射）制剂皮下输注在健康受试者中的药代动力学特征及绝对生物利用度的临床试验
本试验为以注射用头孢唑林钠（日本原研）静脉输注作为对照，比较注射用BJ009（皮下注射）制剂皮下输注在健康受试者中的药代动力学特征及绝对生物利用度
开始日期2025-12-30 |
申办/合作机构 |
CTIS2024-516232-10-00
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
开始日期2025-12-01 |
100 项与 头孢唑林钠 相关的临床结果
登录后查看更多信息
100 项与 头孢唑林钠 相关的转化医学
登录后查看更多信息
100 项与 头孢唑林钠 相关的专利（医药）
登录后查看更多信息
8,896
项与 头孢唑林钠 相关的文献（医药）2026-04-01·Infectious Diseases Now
Antibiotic tolerance and safety in infective endocarditis: A focus on older patients
Article
作者: Richard, Capucine ; Gautier, Sylvain ; Perrineau, Ségolène ; Pépin, Marion ; Dinh, Aurélien ; Jaffal, Karim ; Mansencal, Nicolas ; Tardy, Valérie Sivadon ; DE Chazournes, Pierre Boisson ; Charron, Cyril
BACKGROUND:
Infective endocarditis (IE) is a rare but severe disease with high morbidity and mortality, increasingly affecting older adults. Data on antibiotic tolerance in this population remain limited.
METHODS:
We conducted a hospital network cohort study including all patients over 65 years old. diagnosed with IE between May 2016 and August 2024 in the greater Paris area. Antibiotic-related adverse events (AEs) were systematically collected, within six months of follow-up.
RESULTS:
Among 83 patients (median age: 84 years), 21 (25.3%) experienced at least one AE. Patients with AEs had longer hospital stays but similar age, autonomy, and in-hospital outcomes compared to those without AEs. Cognitive impairment was significantly associated with a higher risk of AEs, particularly in patients aged ≥ 75 years. Streptococcal IE was less frequently associated with AEs. Most AEs were biological abnormalities or clinical events, mainly involving amoxicillin and cefazolin.
CONCLUSIONS:
Age alone did not markedly affect antibiotic tolerance.
2026-04-01·American Journal of Obstetrics & Gynecology MFM
Azithromycin to improve latency in examination-indicated cerclage: a multicenter randomized controlled trial
Article
作者: Rosenfeld, Emily B ; Rosenfeld, Emily B. ; Fischer, Stephanie A. ; Boelig, Rupsa C ; Khanuja, Kavisha ; Piacquadio, Megan ; Miller, Emily S ; Jayakumaran, Jenani S ; Boelig, Rupsa C. ; Kalifeh, Adeeb ; Fischer, Stephanie A ; Brandt, Justin S ; Brandt, Justin S. ; Jayakumaran, Jenani S.
BACKGROUND:
Physical examination-indicated cerclage is an intervention offered to prolong pregnancy in the setting of painless cervical dilation before 24 weeks of gestation. Of note, 1 randomized clinical trial showed an increased incidence of pregnancy prolongation by at least 28 days among participants who received perioperative indomethacin and cefazolin in the setting of a physical examination-indicated cerclage compared with those who did not receive those perioperative medications. Prospective studies have suggested that prophylactic azithromycin may increase latency in the setting of cervical shortening. However, this has not been studied in a controlled manner in patients undergoing physical examination-indicated cerclage.
OBJECTIVE:
This study aimed to determine whether the addition of perioperative azithromycin to cefazolin and indomethacin for physical examination-indicated cerclage increases the latency to delivery compared with perioperative cefazolin and indomethacin alone.
STUDY DESIGN:
This was an open-label multicenter randomized controlled trial of individuals with singleton gestations who were undergoing a physical examination-indicated cerclage between December 2021 and September 2023 at 4 sites across the United States. This study was approved by the institutional review board and was registered on ClinicalTrials.gov (registration number: NCT05132829). Participants were randomized 1:1 via a computer-generated randomization sequence stratified by site to standard of care (cefazolin 1-2 g intravenously and indomethacin 50 mg preoperatively followed by 2 additional doses at 8 and 16 hours postoperatively, control arm) or standard of care plus azithromycin (azithromycin 1000 mg intravenously in addition to cefazolin and indomethacin described in the control group, azithromycin arm). The primary outcome was gestational latency (days) from cerclage placement to delivery. The secondary outcomes included preterm birth, gestational age at delivery, chorioamnionitis, and neonatal morbidity and mortality.
RESULTS:
A total of 82 pregnant individuals were assessed for eligibility, and 54 participants were randomized, 27 to the control arm and 27 to the azithromycin arm. In the primary intention-to-treat analysis, the median gestational latency from cerclage placement to delivery did not differ between the intervention and control groups (92 days [interquartile range, 45-118] vs 85 [interquartile range, 20-123] days, respectively; P=.93). Furthermore, there was no statistically significant difference found in any of the secondary obstetrical or neonatal outcomes.
CONCLUSION:
A single perioperative dose of azithromycin in addition to standard of care cefazolin and indomethacin does not improve the latency to delivery or other perinatal outcomes compared with standard of care alone in patients with singleton gestations undergoing a physical examination-indicated cerclage.
2026-03-01·JOURNAL OF HOSPITAL INFECTION
Surgical antibiotic prophylaxis in women undergoing caesarean delivery: a systematic review of clinical practice guidelines
Review
作者: Onakpoya, I J ; Burgert, J ; Looby, A ; Wade, T ; Heneghan, C J ; Roberts, N
BACKGROUND:
Clinical practice guidelines (CPGs) are essential in hospitals to guide the use of surgical antibiotic prophylaxis for women delivering via caesarean section (c-section). Although CPGs exist, the quality of these documents is infrequently examined.
OBJECTIVE:
The purpose of this systematic review is to examine the quality of CPGs directing the use of antibiotic prophylaxis in c-sections and review the evidence informing current recommendations.
SEARCH STRATEGY:
We systematically searched Medline, EMBASE and LILACS for publications which included recommendations for surgical antibiotic prophylaxis in caesarean deliveries published between 2015 and 2025. Google Scholar, databases of organisations and reference lists of included studies were also searched.
SELECTION CRITERIA:
Two reviewers independently screened the titles and abstracts of the retrieved publications. Two reviewers independently screened articles identified for full-text review.
DATA COLLECTION AND ANALYSIS:
Data were independently collected by two reviewers using a standardised data collection tool. Discrepancies were resolved via discussion.
MAIN RESULTS:
Eleven guidelines from several geographical regions were included in the review. Pre-incision cefazolin was explicitly recommended by 45% of guidelines. When appraised using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool, the methodological quality of guidelines varied substantially for four of the examined domains. Stakeholder involvement had a median score of 54% (range: 7-96), rigour of development 43% (4-97), applicability 14% (0-88) and editorial independence 58% (0-100). Information relevant to guideline development was not accessible for some CPGs.
CONCLUSION:
CPG development should be a rigorous process, with all information about development made easily accessible for the users and recipients of the practice recommendations.
REGISTRATION:
https://osf.io/vqgpm.
204
项与 头孢唑林钠 相关的新闻（医药）2026-02-12
引用本文：
支阳,董一诺,雷晓红,茅益民. 2025年药物性肝损伤领域研究进展[J]. 中华肝脏病杂志,2026,34(01)：18-20.DOI:10.3760/cma.j.cn501113-20251212-00528.
通信作者 ：
茅益民，上海交通大学医学院附属仁济医院消化内科 上海市消化疾病研究所 上海市脂肪性肝病诊治研究中心
摘 要
2025年，药物性肝损伤（DILI）研究在国际协作网络建设、特定药物相关 DILI 的临床特点刻画、遗传易感性与预后预测模型等方面取得了重要进展。与此同时，免疫检查点抑制剂相关肝损伤治疗药物的研究不断深入，药物全生命周期肝毒性监管持续加强，人工智能在 DILI 风险识别及患者支持中的应用日益受到关注。
2025年度，药物性肝损伤（drug-induced liver injury，DILI）领域的临床和转化研究取得一定进展，本文选取部分关键临床研究概括如下。
一、
法语区药物肝毒性研究网络
的前瞻队列
作为全球药物性肝损伤协作网络的一部分，法国和比利时于2021年建立了法语区药物肝毒性研究网络（Réseau d'Etude Francophone de l' Hépatotoxicité des Produits de Santé，REFHEPS），并启动了前瞻队列研究。2025年，REFHEPS报告了280例DILI患者的主要病因和临床特征 ［ 1 ］ ，超过半数的致肝损伤药物为各类抗肿瘤药。尽管该队列反映了当代肿瘤治疗背景下新兴的DILI病因谱，但鉴于参与中心多为肿瘤中心，其无法完全代表普通人群中DILI的真实构成。
二、
特定药物导致的DILI
1.抗生素：抗生素是DILI的常见病因，2025年度，美国药物性肝损伤网络（Drug-Induced Liver Injury Network，DILIN）报道了头孢菌素和氟喹诺酮类药物导致肝损伤的特点及其遗传易感性。头孢菌素-DILI常以自限性的胆汁淤积或混合型肝损伤为特征，头孢唑啉是最常见致病药物；HLA-A*02∶01的基因多态性可能与头孢菌素-DILI相关，患者的肝损伤通常更重 ［ 2 ］ 。氟喹诺酮-DILI以短潜伏期、多样的肝损伤模式，以及显著的慢性化和死亡风险为特点；HLA-DQA1*03∶01和HLA-B*57∶01基因型可能与氟喹诺酮-DILI显著相关 ［ 3 ］ 。因此，不同抗生素导致肝损伤的临床特点和遗传易感性不尽相同。
2.草药和膳食补充剂：草药和膳食补充剂（herb and dietary supplements）是DILI的重要病因，其损伤的多样性、隐匿性使临床诊治和防范面临很大挑战。今年发布的一项随机安慰剂对照试验首次明确了大麻二酚在健康个体中可引起剂量相关的丙氨酸转氨酶升高，近5%的患者达到DILI诊断标准 ［ 4 ］ 。此外，HDS-DILI领域，今年还报道了荔枝草 ［ 5 ］ 、过量服用含薄荷油的保健品等导致的肝损伤 ［ 6 ］ 。
3.甲泼尼龙：甲泼尼龙是治疗超敏或自身免疫性疾病、免疫介导肝损伤的常用药物，然而，其潜在的肝毒性应引起临床关注。来自DILIN的数据显示，静脉甲泼尼龙可诱发伴有黄疸的肝细胞型DILI，尤其是在高剂量连续多日使用后，尽管多数患者预后良好，但也报道了有个别患者需接受肝移植治疗 ［ 7 ］ 。
三、
DILI的遗传易感性
遗传易感性可能是特定人群暴露于特定药物后导致DILI发生、重症化的重要风险因素。2025年度，多项研究聚焦于此领域：鸟苷酸结合蛋白4基因的错义变异可能与DILI进展为急性肝衰竭的风险显著降低相关 ［ 8 ］ ；HLA-A*32∶01、HLA-B*53∶01和HLA-B*58∶01等等位基因显著富集于同时出现伴嗜酸粒细胞增多和全身症状的药物反应综合征（drug reaction with eosinophilia and systemic sympto-ms，DRESS）的DILI患者，强调了免疫遗传因素对超敏反应型肝损伤的影响 ［ 9 ］ ；此外，含PATATIN样磷脂酶域蛋白3多态性显著增加化学治疗相关脂肪性肝炎及更严重肝损伤的风险 ［ 10 ］ 。
四、
DILI的预后预测
急性DILI患者中如何识别可能出现重症化或慢性化等不良临床结局的风险人群一直是研究热点。2025年度，多项研究聚焦于此：新提出的DILI-Inpt评分（包括入院时总胆红素、国际标准化比值、肝性脑病等级及草药使用情况等） ［ 11 ］ 、肝脏组织学特征（出现严重坏死、胆管样增生等） ［ 12 ］ ，被报道可能与死亡风险或需肝移植相关。此外，基于身体质量指数、血红蛋白、自身抗体、初始严重度及胆汁转运蛋白表达的预测模型，报道可提前识别具有慢性化风险的患者 ［ 13 ］ 。
五、
DILI的治疗
糖皮质激素是目前免疫检查点抑制剂相关肝损伤（checkpoint inhibitor-induced liver injury，ChILI）的主流治疗方案。2025年度，多项研究探讨了激素以外的治疗药物：国内报道的异甘草酸镁和激素联合治疗的疗效优于激素单药治疗，并可减少激素剂量 ［ 14 ］ ；熊去氧胆酸治疗胆汁淤积型ChILI时可取得较好的疗效 ［ 15 ］ ；英夫利昔单克隆抗体作为挽救治疗方案（当前指南不推荐）治疗激素应答不佳难治性ChILI的疗效和安全性 ［ 16 ］ 。
此外，一项随机、对照研究报道，在对乙酰氨基酚过量的低风险患者中（摄入<30 g且8 h内就诊），12 h静脉乙酰半胱氨酸（每4 h 200 mg/kg，每8 h 50 mg/kg）的疗效不劣于传统的20 h方案，并显著缩短了治疗时间 ［ 17 ］ 。
六、
药物研发和药品上市后肝毒性的
全程管理：监管机构视角
DILI的风险识别是新药研发中的关键，2025年度发表在 Hepatology上的综述系统阐述了药物在研发全过程中的DILI风险评估策略 ［ 18 ］ 。此外，美国食品药品管理局（Food and Drug Administration，FDA）对73个临床试验中的DILI病例进行回顾，发现临床试验中采用新R值（new R ratio，nR）可更敏感、准确地识别符合 Hy's law 的高风险病例 ［ 19 ］ 。同时，FDA新发布了DILIrank 2.0数据库，其收录了1 336种药物，并根据药品说明书、因果关系评估和文献证据对上市药物的DILI风险进行了分类 ［ 20 ］ 。
七、
人工智能的应用
人工智能是医药领域未来发展的重要方向。在DILI领域，国内报道的一项研究系统评估了多种主流大语言模型在DILI患者教育方面的表现，结果显示部分模型在准确性、全面性和安全性方面均有较好表现，提示大语言模型未来在DILI患者教育与信息支持中具有重要的应用潜力 ［ 21 ］ 。此外，国内报道的利用机器学习开发的一种数学模型，认为可区分特异质型DILI和自身免疫性肝炎 ［ 22 ］ 。
参考文献
[1]Meunier L ,Delire B ,DeMartin E ,et al. Features and outcomes of 280 patients with idiosyncratic drug-induced liver injury:the refheps prospective study[J/OL]. Clin Gastroenterol Hepatol, 2025. 23(2025-11-04)[2025-12-12]. https://pubmed.ncbi.nlm.nih.gov/41197933/. DOI: 10.1016/j.cgh.2025.10.024 published online ahead of print. [ ].
[2]Vuppalanchi R ,Li YJ ,Rockey DC ,et al. Clinical and genetic associations in cephalosporin-induced liver injury:insights from the Drug-Induced Liver Injury Network[J]. Aliment Pharmacol Ther, 2025,62(10):1012-1022. DOI: 10.1111/apt.70284 .
[3]Ahmad J ,Dellinger A ,Nicoletti P ,et al. Clinical and HLA associations of fluoroquinolone-induced liver injury:results from the Drug-Induced Liver Injury Network[J/OL]. Am J Gastroenter-ol, 2025,120(2025-04-10)[2025-12-12]. https://pubmed.ncbi.nlm.nih.gov/40207808/. DOI: 10.14309/ajg.0000000000003457 published online ahead of print. [ ].
[4]Florian J ,Salcedo P ,Burkhart K ,et al. Cannabidiol and liver enzyme level elevations in healthy adults:a randomized clinical trial[J]. JAMA Intern Med, 2025,185(9):1070-1078. DOI: 10.1001/jamainternmed.2025.2366 .
[5]周慧慧,高玉卯,马翠梅,等. 荔枝草相关药物性肝损伤16例临床特征分析[J]. 中国实用医刊, 2025,52(17):24-28. DOI: 10.3760/cma.j.cn115689-20250408-00039 .
[6]Ali K ,AlSnih GM ,Beyder A ,et al. Peppermint oil-associated hepatotoxicity[J]. J Hepatol, 2025,83(2):e77-e78. DOI: 10.1016/j.jhep.2025.04.004 .
[7]Ahmad J ,Li YJ ,Phillips E ,et al. Liver injury due to intravenous methylprednisolone in the Drug-Induced Liver Injury Network[J]. Liver Int, 2025,45(2):e16242. DOI: 10.1111/liv.16242 .
[8]Liao TJ ,Xia M ,Hayashi P ,et al. Genetic variants of GBP4: reduced risks for drug-induced acute liver failure in non-finnish european population[J]. Liver Int, 2025,45(2):e70011. DOI: 10.1111/liv.70011 .
[9]Rahnama-Moghadam S ,Arora N ,Vuppalanchi R ,et al. DRESS syndrome in patients with drug-induced liver injury:characteris-tics and HLA risk factors[J/OL]. Am J Gastroenterol, 2025,120(2025-06-12)[2025-12-12]. https://pubmed.ncbi.nlm.nih.gov/40504263/. DOI: 10.14309/ajg.0000000000003590 published online ahead of print. [ ].
[10]Rumpf B ,Santol J ,Kern AE ,et al. PNPLA3 polymorphism worsens chemotherapy associated liver injury and affects overall survival in colorectal cancer patients with liver metastasis undergoing hepatic resection[J]. EBioMedicine, 2025,120:105928. DOI: 10.1016/j.ebiom.2025.105928 .
[11]Likhitsup A ,Su Z ,Rule JA ,et al. The DILI-inpt prognostic score to identify hospitalized idiosyncratic DILI patients at risk for adverse outcomes[J/OL]. Clin Gastroenterol Hepatol. 2025,23(2025-11-19)[2025-12-12]. https://pubmed.ncbi.nlm.nih.gov/41270879/. DOI: 10.1016/j.cgh.2025.11.004 published online ahead of print. [ ].
[12]Weber S ,Erhardt F ,Neumann J ,et al. Histopathological changes as a predictor of fatal outcome in patients with drug-induced liver injury[J]. Liver Int, 2025,45(7):e70182. DOI: 10.1111/liv.70182 .
[13]Bihari C ,Sharma S ,Giri A ,et al. Model of baseline clinicopathological features predicts non-resolution of drug-induced liver injury at 6 months[J]. Hepatol Int, 2025,19(3):633-646. DOI: 10.1007/s12072-025-10814-6 .
[14]Zhi Y ,Dong Y ,Li X ,et al. Magnesium isoglycyrrhizinate combined with steroid is superior to steroid monotherapy in checkpoint inhibitor-induced liver injury[J]. Liver Int, 2025,45(9):e70310. DOI: 10.1111/liv.70310 .
[15]Hountondji L ,Faure S ,Palassin P ,et al. Ursodeoxycholic acid alone is effective and safe to treat cholestatic checkpoint inhibitor-induced liver injury[J]. Liver Int, 2025,45(5):e70073. DOI: 10.1111/liv.70073 .
[16]Oliva KN ,Arnold L ,Heinzerling L ,et al. Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis[J]. J Immunother Cancer, 2025,13(9):e013038. DOI: 10.1136/jitc-2025-013038 .
[17]Isbister G ,Chiew A ,Buckley N ,et al. A non-inferiority randomised controlled trial of a shorter acetylcysteine regimen for paracetamol overdose-the SARPO trial[J]. J Hepatol, 2025,83(4):881-887. DOI: 10.1016/j.jhep.2025.05.008 .
[18]Chalasani N ,Hayashi PH ,Luffer-Atlas D ,et al. Assessment of liver injury potential of investigational medicines in drug development[J]. Hepatology, 2025,82(2025-02-25)[2025-12-12]. https://pubmed.ncbi.nlm.nih.gov/39999469/. DOI: 10.1097/HEP.0000000000001281 Epub ahead of print. [ ].
[19]Amirzadegan J ,Vouffo EC ,Lan L ,et al. R Value-based criteria outperform alkaline phosphatase less than twice normal in identifying Hy’s law cases in clinical trials[J]. Drug Saf, 2025,48(2025-08-31)[2025-12-12]. https://link.springer.com/article/10.1007/s40264-025-01603-z. DOI: 10.1007/s40264-025-01603-z published online ahead of print. [ ].
[20]Olubamiwa AO ,Qu Y ,Connor S ,et al. DILIrank 2.0:An updated and expanded database for drug-induced liver injury risk based on FDA labeling and a literature review[J]. Drug Discov Today, 2025,30(11):104485. DOI: 10.1016/j.drudis.2025.104485 .
[21]Dong Y ,Zhang Z ,Zhi Y ,et al. Evaluating large language models’ performance in answering common questions on drug-induced liver injury[J]. JHEP Rep, 2025,7(12):101579. DOI: 10.1016/j.jhepr.2025.101579 .
[22]Wang Y ,Lin X ,Sun Y ,et al. Development and validation of a novel model to discriminate idiosyncratic drug-induced liver injury and autoimmune Hepatitis[J]. Liver Int, 2025,45(2):e16239. DOI: 10.1111/liv.16239 .
版权声明
本文为《中华肝脏病杂志》原创文章，版权归中华医学会所有。其他媒体、网站、公众号等如需转载本文，请联系本刊编辑部获得授权，并在文题下醒目位置注明“原文刊发于《中华肝脏病杂志》，卷（期）：起止页码”。谢谢合作！
2026-02-12
·搜狐新闻
采用MonolixSuite软件发表的部分参考文献汇总（2024年7月-2025年12月）导读凡默谷技术部挑选了2024年7月—2025年12月全球采用MonolixSuite软件发表或涉及MonolixSuite综述的部分应用文章。希望对您的业务或专业学习有所帮助。本公众号不提供文章的原文下载，如您想了解某篇文章的详情，请下载《采用MonolixSuite软件发表的部分参考文献汇总列表 2024年7月-2025年12月》PDF版文件，有对应文章的介绍链接。2024年7月-2025年12月 PDF版文献汇总列表下载(复制链接到浏览器）https://www.jianguoyun.com/p/DfVhFxUQ_a64Bxih9ZkGIAA访问密码：HdX0tA01中国用户发表的部分文章或涉及到的综述用于预测拓扑异构酶抑制剂ADC药物在小鼠及人体内的药代动力学、肿瘤生长抑制效应及毒性风险的 PBPK-PD 模型PBPK-PD model for predicting pharmacokinetics, tumor growth inhibition, and toxicity risks of topoisomerase inhibitor ADCs in mice and humans西维来司他钠在中国重症肺炎患者中的群体药代动力学研究Population pharmacokinetics of sivelestat in Chinese patients with severe pneumoniaZhang X., Hu H., Li Z., Zhang P., Pan L., Wang L., Mao J., Li F., Zhang L. Fundamental and Clinical Pharmacology. 2025 39:2 Article Number e70001亚胺培南在感染性实体瘤患者中的群体药代动力学：一项真实世界研究Population pharmacokinetics of imipenem in solid tumor patients with infections: A real-world studyXu T., Zou T., Zhang J., Li Z., Li F., Du J., Hao Z. Journal of Global Antimicrobial Resistance. 2025 45 (107-114)PopPK和PBPK模型指导美罗培南在重症患儿增强肾脏清除率下的剂量优化PopPK and PBPK Models Guide Meropenem Dosing in Critically Ill Children with Augmented Renal ClearanceLiu Y., He H., Zhang S.-S., Zhou J., Zhu J.-W., Xu J., Miao H.-J., Chen J.-H., Hao K. Pharmaceutics. 2025 17:12 Article Number 1544达泊西汀在健康中国男性受试者中的群体药代动力学Population Pharmacokinetics of Dapoxetine in Healthy Chinese Male SubjectsPu L., Wu T., Bai F., Lu H., Wang Y., Gao Y., Qiu W. Journal of Clinical Pharmacology. 2025丙泊酚注射液的群体药代动力学研究进展陈浩，陈建恒，吕洁，严泽林，卞民亮，陆程灿.《临床药物治疗杂志》. 第24 卷 第1 期, 2026年1月02其他国家用户发表的部分文章或相关的综述基于模型的荟萃分析应用 MonolixSuite：针对纵向分类与连续数据的教程Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous DataBracis C., Taneja A., Lyauk Y.K., Barcomb H., de la Peña A., Cellière G.CPT: Pharmacometrics and Systems Pharmacology2026 15:2 Article Number e70158 高强度间歇性运动对二甲双胍在健康男性的药代动力学影响——基于PopPK模型的评估Effect of high-intensity interval exercise on metformin pharmacokinetics in healthy men, assessed through a population pharmacokinetic modelNikolaidis S., Kosmidis I., Papadopoulos S., Lioupi A., Gandanidou M., Gika H., Dokoumetzidis A., Theodoridis G., Mougios V. British Journal of Pharmacology. 2026 183:3 (438-452) 抗胸腺细胞球蛋白在髓消性造血干细胞移植中的PopPK与最佳药物暴露Population pharmacokinetics and optimal exposure of anti-thymocyte globulin in myeloablative hematopoietic cell transplantationGhazal H., Leuchter S., Ngo R., Kinzel M., Dabas R., DharmaniKhan P., Khan F.M., Jamani K., Li N., Kiang T.K., Storek J. Transplantation and cellular therapy. 2026 他克莫司口服混悬液在造血干细胞移植患儿中的PopPK及生物利用度研究Population pharmacokinetics and bioavailability of tacrolimus oral suspension in children with haematopoietic stem cell transplantBrstilo L., Ibarra M., Juliá A., Testard J., Salgueiro R., Mendoza A., Pérez C., Licciardone N., Marquet P., Staciuk R., Buontempo F., Schaiquevich P. British Journal of Clinical Pharmacology. 2026 92:1 (210-219) 从 AUC/MIC 到 AUCss 与 Cmin：通过模型引导米卡芬净在危重患者治疗中的精准给药的优化From AUC/MIC to AUCss and Cmin: Optimizing Micafungin Therapy in the Critically Ill through Model-Informed Precision DosingBerrah R., Saint Marcoux F., Monchaud C., Cointault O., Conseil M., Jaber S., Jung B., Woillard J.B. AAPS Journal2026 28:1 Article Number 18阿莫西林在人乳中的PopPK建模——ConcePTION 项目的一项贡献Population pharmacokinetic modelling of amoxicillin in human breast milk—A contribution from the ConcePTION projectBaklouti S., Rigourd V., Panchaud A., Nordeng H., Allegaert K., Annaert P., Huang M.-C., Monfort A., Guidi M., Gandia P. British Journal of Clinical Pharmacology. 2026重症监护病房（ICU）收治的医院获得性肺炎患者中，他唑巴坦联合哌拉西林给药的关键阈值目标达标率Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia含删失协变量和测量误差的广义线性混合模型及其在 HIV/AIDS 研究中的应用Generalized Linear Mixed Models with Censored Covariates and Measurement Errors, with Applications in HIV/AIDS StudiesGao S., Wu L. Statistics in Biosciences. 2025 17:3 (832-854)神经重症监护人群中左乙拉西坦给药方案的优化：Neuro-ARC 研究Levetiracetam Dosing Optimization in Neurocritical Care Population: Neuro-ARC StudyKharouba M., Cook A.M., Bastin M.L.T., Kutsogiannis D.J., Mahmoud S.H. Neurocritical Care. 2025 43:3 (887-901)结合人胎盘离体灌注数据与PBPK建模预测艾司西酞普兰、舍曲林和帕罗西汀在母亲及胎儿中的药物暴露Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic ModelingPréta L.-H., Bouazza N., Foissac F., Froelicher L., Urien S., Buth V., Benaboud S., Tréluyer J.-M., Lui G. Clinical Pharmacokinetics. 2025 64:12 (1843-1854)ADC药物的上市后评估：基于模型荟萃分析和临床效用指数方法支持临床概念验证Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index ApproachAsiimwe I.G., Chtiba N., Mouksassi S., Pillai G., Peter R.M., Yuen E., Pilla Reddy V. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:11 (1810-1822)基于全身动态 PET 微剂量给药数据建立人体格列吡嗪全身药代动力学预测模型Modeling Whole-Body Dynamic PET Microdosing Data to Predict the Whole-Body Pharmacokinetics of Glyburide in HumansComin L., Marie S., Ursino M., Zohar S., Tournier N., Comets E. Clinical Pharmacokinetics. 2025 64:11 (1709-1722)家庭接触者中 SARS-CoV-2 检测的时间动态：首次阳性检测时间、症状出现时间与病毒载量峰值时间的差异Temporal Dynamics of SARS-CoV-2 Detection in Household Contacts: Divergences Between Time to First Positive Test, Symptom Onset, and Maximum Viral Load成人肺移植受者术后早期霉酚酸PopPK及贝叶斯评估Population pharmacokinetics of mycophenolic acid and Bayesian estimator in lung transplant adults recipients in the early post-transplant period抗中性粒细胞胞浆抗体（ANCA）相关性血管炎中利妥昔单抗诱导与维持治疗方案的比较：基于真实世界患者 ANCA 及丙种球蛋白水平的PK/PD分析Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patientspH 值对德拉沙星抗大肠杆菌等基因株抗菌活性的影响：针对不同染色体和质粒介导的氟喹诺酮类耐药机制的研究Effect of pH on antimicrobial activity of delafloxacin against Escherichia coli isogenic strains carrying diverse chromosomal and plasmid-mediated fluoroquinolone resistance mechanisms头孢唑林在儿科心脏手术患者中作为预防用药的PopPK研究Population pharmacokinetics of cefazolin administered as prophylaxis in paediatric patients undergoing cardiac surgery比较 COVID-19 疫苗接种后未感染者和康复者随时间变化的中和抗体活性Comparing neutralizing antibody activity over time between naïve and convalesced COVID-19 vaccinated individualsPillis L., Caffrey R., Chen G., Dela M., Eldevik L., Liu H., McConnell J.P., Shabahang S., Varvel S.A. Scientific reports. 2025 15:1 (34800-)泼尼松龙在系统性红斑狼疮患者中的PopPK建模：暴露量与疾病活动度分析Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity利妥昔单抗治疗多发性硬化症临床预试验中的PK-PD建模：迈向个性化给药间隔的研究Pharmacokinetic–pharmacodynamic modelling in a clinical pilot study of rituximab in multiple sclerosis: Towards personalized dosing interval采用PopPK模型优化危重症难治性和超难治性癫痫持续状态患者的苯巴比妥给药方案Optimizing phenobarbital dosing in critically ill patients with refractory and superrefractory status epilepticus using a population pharmacokinetic model妊娠对囊性纤维化女性患者中 elexacaftor、tezacaftor 和 ivacaftor 药代动力学的影响Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in cystic fibrosis womenMagnas P., Bouazza N., Foissac F., Froelicher-Bournaud L., Lui G., Carlier N., Da Silva J., Fesenbeckh J., Kanaan R., Honoré I., Martin C., Treluyer J., Tsatsaris V., Burgel P., Benaboud S. Journal of Cystic Fibrosis. 2025 24 Supplement 2 (S279a-S280)HIV 感染者中比克替拉韦的群体药代动力学：真实世界研究Population pharmacokinetics of bictegravir in real-world people with HIV社区获得性肺炎重症患者经持续输注高剂量头孢吡普后的肺内浓度研究Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia血管紧张素 II/血管紧张素 I 比值作为接受依那普利治疗的健康成年受试者和心力衰竭儿童患者群体建模的一项新的药效学参数Angiotensin II/Angiotensin I Ratio as a New Pharmacodynamic Parameter for Population Modelling in Healthy Adults and Children with Heart Failure Treated with EnalaprilSteichert M., Cawello W., Burckhardt B.B., Suessenbach F.K., Laeer S. Pharmaceutics. 2025 17:10 Article Number 1345精确调整达托霉素给药剂量：3 种、2 种、1 种及 0 浓度取样方案比较Precision Daptomycin Dosing: Comparison of 3-, 2-, 1-, and 0-Concentration Sample StrategiesGiuliano S., Pai M.P., Angelini J., Flammini S., Martini L., Baraldo M., Tascini C. Pharmacotherapy. 2025 45:9 (540-546)针对接受肾脏替代治疗的危重患者的美罗培南和哌拉西林/他唑巴坦优化给药方案Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapyRoberts J.A., Ulldemolins M., Liu X., et al. Intensive Care Medicine. 2025 51:9 (1628-1640)基于PopPK模型优化利奈唑胺给药方案：针对疑似或确诊革兰阳性菌败血症的血液肿瘤患者Population Pharmacokinetic Model-Based Optimization of Linezolid Dosing in Hematooncological Patients With Suspected or Proven Gram-Positive SepsisZavřelová A., Merdita S., Žák P., Radocha J., Víšek B., Lánská M., Maláková J., Michálek P., Slanař O., Šíma M. Clinical and Translational Science. 2025 18:9 Article Number e70346IgG 编码 mRNA的多尺度机理药代动力学—毒代动力学（PK-TK）建模在基础研究到临床的应用：以抗 Claudin 18.2 抗体为例Bench to Bedside Modeling of mRNA Encoding IgG Using a Multiscale Mechanistic Pharmacokinetic-Toxicokinetic (PK-TK) Model: A Case Study With Anti-Claudin 18.2Desai D.A., Cristofoletti R. Clinical and Translational Science. 2025 18:9 Article Number e70356使用 SVG-101 群体药动学模型评估其合理的剂量选择Application of population pharmacokinetic modeling of SVG-101 to evaluate proper dose selectionMo K.H., Chae D., Jung Y.S., Jin B.H., Keum D.H., Choi M.K., Cha J.S., Park M.S., Kim C.O. Translational and Clinical Pharmacology. 2025 33:3 (156-167)2 型糖尿病患者代谢年龄和实际年龄vs碘海醇药代动力学的相关性Correlation of Metabolic Age & Calendar Age to Iohexol Pharmacokinetics in Patients With Type 2 DiabetesAlikhani R., Hooper L., Matvekas A., Waltje A., Rothberg A., Pai M. Clinical Pharmacology in Drug Development. 2025 14 Supplement 1 (6-7)通过群体PK/PD模拟评估替格瑞洛给药剂量中断及恢复治疗（含或不含负荷剂量）的效果Evaluation of the Effect of Ticagrelor Dose Interruption and Treatment Resumption with or without Bolus Doses Through Population PK/PD SimulationMatsui H., Pham L.T.T., Adane E. European Journal of Drug Metabolism and Pharmacokinetics. 2025 50:5 (409-418)缬更昔洛韦预防巨细胞病毒感染的目标达成情况Target attainment of valganciclovir prophylaxis against cytomegalovirusWenker S., Van Hasselt C., Moes D., Märtson A. British Journal of Clinical Pharmacology. 2025 91 Supplement 1 (8-9)胺碘酮对心脏手术后患者中阿哌沙班药物暴露的影响：一项群体药代动力学研究Effect of Amiodarone on Apixaban Exposure in Patients after Cardiac Surgery—A Population Pharmacokinetic StudyMorath B., Foerster K.I., Chiriac U., Zaradzki M., Hoppe-Tichy T., Schrey D., Burhenne J., Czock D., Karck M., Haefeli W.E., Wicha S.G. Clinical Pharmacokinetics. 2025 64:8 (1191-1201)非甾体抗炎药在山地超级越野跑者干血斑中的定量分析：PK模型对结果解读的贡献Quantitative analysis of nonsteroidal anti-inflammatory drugs in dried blood spot from mountain ultra-trail runners. Contribution of pharmacokinetic models for the interpretation of the resultsMashal M.S., Guitton J., Sallet P., Bourguignon L., Machon C. Drug Testing and Analysis. 2025 17:6 (825-833)比较不同胰岛素类型的疗效：健康受试者葡萄糖钳夹效应的PK-PD建模Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy VolunteersChang Y.C., Jusko W.J. Journal of Clinical Pharmacology. 2025 65:8 (999-1010)评估多重插补算法对PK模型性能的影响：一项基于模拟的研究Assessing the Impact of Multiple Imputation Algorithms on Pharmacokinetic Model Performance: A Simulation-Based StudyDuflot T., Fayette L., Konecki C., Seurat J., Feliu C., Scala-Bertola J., Djerada Z.AAPS Journal. 2025 27:4 Article Number 77量化影响常染色体显性肾小管间质肾病进展速度和严重程度的临床及遗传因素Quantifying clinical and genetic factors influencing rate and severity of autosomal dominant tubulointerstitial kidney disease progressionRamesh S.S., Rogge M., Kidd K.O., Williams A.H., Yoon D.Y., Roignot J., Blakeslee K., Bleyer A.J., Kim S. Journal of Pharmacokinetics and Pharmacodynamics. 2025 52:4 Article Number 41甲氨蝶呤的治疗药物监测、PopPK建模及在儿童急性淋巴细胞白血病患者高剂量给药的外部验证Therapeutic Drug Monitoring, Population Pharmacokinetics Models, and External Validation of High-Dose Methotrexate in Pediatric Acute Lymphoblastic LeukemiaMaximova N., Calabrò P.F., Cangialosi A., Di Paolo A. Chemotherapy. 2025 70:3 (109-118)危重症儿童尿液生物标志物与头孢吡肟治疗目标达成的关联研究Urinary Biomarkers and Attainment of Cefepime Therapeutic Targets in Critically Ill ChildrenDownes K.J., Sharova A., Amajor V., Gianchetti L., Himebauch A.S., Fitzgerald J.C., Zuppa A.F. Pediatric Infectious Disease Journal. 2025 44:8 (749-754)Andalusian马体内静脉注射对乙酰氨基酚及其代谢物后的群体药代动力学和临床评估研究Population pharmacokinetics and clinical evaluation of intravenous acetaminophen and its metabolites in Andalusian horses预测妊娠期间他克莫司的游离浓度Predicting Unbound Tacrolimus Concentrations during PregnancyLeino A., Wilson N.K., Kataria A.D., Hebert M.F. American Journal of Transplantation. 2025 25:8 Supplement 1 (S204-)AEROfen：一项 I 期临床、开放标签、随机交叉研究方案，通过PK模型评估健康受试者中雾化芬太尼的给药效率—比较面部与鼻内给药途径AEROfen: protocol for a phase I, open-label, randomised crossover study evaluating the efficiency of nebulised fentanyl in healthy volunteers - comparing facial versus intranasal administration via pharmacometric modellingFollet C., Dumont A., Roussel M., Gillibert A., Boedard C., Quillard M., Ruault S., Vallin F., Donnadieu N., Nunes Ferreira D., Pereira T., Joly L.-M., Lvovschi V., Duflot T. BMJ Open. 2025 15:7 Article Number e091125超越线性模型的浓度- QT 分析Beyond the linear model in concentration‑QT analysisGéraldine Cellière, Andreas Krause, Guillaume Bonnefois, Jonathan Chauvin. Journal of Pharmacokinetics and Pharmacodynamics. (2025) 52:311型干扰素介导的系统性红斑狼疮炎症的综合机制模型An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus ErythematosusVolkova A., Sokolov V., Tettamanti F., Verma M., Ugolkov Y., Peskov K., Tang W., Kimko H. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:7 (1225-1235)PK/PD建模与蒙特卡洛模拟预测接受（缬）更昔洛韦治疗的儿科移植受者的巨细胞病毒载量Pharmacokinetic/Pharmacodynamic Modelling and Monte Carlo Simulations to Predict Cytomegalovirus Viral Load in Pediatric Transplant Recipients Treated with (val) GanciclovirKoloskoff K., Franck B., Benito S., Welzel J., Autmizguine J., Theoret Y., Briand A., Ovetchkine P., Woillard J.-B. Clinical Pharmacokinetics. 2025 64:7 (1061-1069)沙特阿拉伯儿童肝移植术后早期他克莫司药代动力学的一项回顾性分析A retrospective analysis of tacrolimus pharmacokinetic in Saudi paediatric patients in early post-liver transplantation periodAlghanem A., Joharji H., Garaween N., Alenazi H., Alsaleh N.A., Broering D., Alshagrani M., Alhassan F., Albassam A.A., Alsultan A., Alsmari A. Pediatrics and Neonatology. 2025 66:4 (368-374)利用纵向患者报告结局轨迹预测非小细胞肺癌生存期Leveraging Longitudinal Patient-Reported Outcome Trajectories to Predict Survival in Non–Small Cell Lung Cancer理解与优化剂量探索：从剂量模拟到剂量估算Understanding and Streamlining Dose Finding: From Dose Simulation to Dose EstimationBräm D., Bachmann F., Schropp J., Gotta V., Steffens B., van den Anker J., Pfister M., Koch G. Journal of Clinical Pharmacology. 2025 65:6 (731-741)基于模型的方法评估抗药物抗体对生物制剂药物暴露的影响：以 CD3 T 细胞双特异性抗体赛必妥单抗为例A Model-Based Approach to Evaluate Anti-Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T-Cell Bispecific CibisatamabSanchez J., Pierrillas P.B., Frey N., Lotz G.P., Jönsson S., Friberg L.E., Frances N. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:6 (1065-1076)基于治疗药物监测, 考察阿米卡星在教学医院患者中的群体药代动力学Therapeutic Drug Monitoring-Based Population Pharmacokinetics of Amikacin in Patients at a Teaching HospitalSteffens N.A., Zimmermann E.S., Azeredo F.J., Linden R., Finatto L.J., Hahn R.Z., Schwarzbold A.V., Pacheco L.S., Brucker N. Antibiotics. 2025 14:6 Article Number 531辅助靶点的药效学评估：低分子量 PBP7/8 对β-内酰胺类药物抗碳青霉烯耐药鲍曼不动杆菌活性的影响Pharmacodynamic Evaluation of Adjuvant Targets: Low Molecular Weight PBP7/8 Effects on β-Lactam Activity Against Carbapenem-Resistant Acinetobacter BaumanniiHo B.M., Jin J., Sanborn J.T., Nguyen T.D., Singh N., Cheng C., Nasief N.N., Carlino-MacDonald U., Tsuji B.T., Zhao Y., Chen L., Moya B., Russo T.A., Smith N.M.Pharmaceuticals. 2025 18:6 Article Number 918WS02.06 Elexacaftor/tezacaftor/ivacaftor在 2 至 5 岁儿童中的药代动力学及行为障碍发生情况WS02.06Elexacaftor/tezacaftor/ivacaftor pharmacokinetics and occurrence of behavioural disorders in children aged 2 to 5 years oldTruong N.H., Benaboud S., Chouchana L., Bonnel A.-S., Barboura M., Bouazza N., Gautier S., Rouillon S., Froelicher-Bournaud L., Bihouee T., Bui S., Treluyer J.-M., Gaudelus I.S., Foissac F., Modul-CF research group. Journal of Cystic Fibrosis. 2025 24 Supplement 1 (S5-)老年群体中皮下注射与静脉注射头孢曲松的药代动力学：PhASAge 研究Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone in an Older Population: The PhASAge StudyRoubaud-Baudron C., Fauchon H., Stanke-Labesque F.,et al. Open Forum Infectious Diseases. 2025 12:6 Article Number ofaf313感染后期植入的 SIV 前病毒存在于寿命较短的 CD4+ T 细胞中SIV proviruses seeded later in infection are harbored in short-lived CD4+ T cells一箭多雕：用于多适应症的肠溶型霉酚酸钠的PopPK模型及贝叶斯估算Killing several birds with one stone: A multi-indication population pharmacokinetic model and Bayesian estimator for enteric-coated mycophenolate sodiumFromage Y., Sayadi H., Koloskoff K., Marquet P., Labriffe M., Monchaud C., Woillard J.-B. British Journal of Clinical Pharmacology. 2025 91:5 (1396-1408)通过PopPL分析优化 1-3 级肥胖患者静脉注射利多卡因的给药方案Dosing optimisation of intravenous lidocaine in patients with class 1–3 obesity by population pharmacokinetic analysisTognolini A.R., Liu X., Pandey S., Roberts J.A., Wallis S.C., Jackson D., Eley V.A. Anaesthesia. 2025 80:5 (511-521)用于考察阿替洛尔与美托洛尔在营养不良大鼠体内吸收的迷你PBPK模型Minimal Physiologically-Based Pharmacokinetic Modeling of Atenolol and Metoprolol Absorption in Malnourished RatsKir F., Sahin S., Jusko W.J. European Journal of Drug Metabolism and Pharmacokinetics. 2025 50:3 (251-263) Article Number e115Elexacaftor/Tezacaftor/Ivacaftor在囊性纤维化儿科患者中的群体药代动力学研究Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic FibrosisTruong N.H., Benaboud S., Bouazza N., Barboura M.,et al. Clinical and Translational Science. 2025 18:5 Article Number e70245比较妊娠妇女在惊厥前期使用 75 mg与 150 mg阿司匹林的效果Comparing 75mg vs 150mg aspirin in pregnancy women at risk of preeclampsiaVinogradov R., Kavanagh O.N., Kamali F., Robson S. American Journal of Obstetrics and Gynecology. 2025 232:5 (e189-e190)克林霉素与利福平联合用药的剂量及给药途径Dosing and route of administration of clindamycin given in combination with rifampicinMagréault S., Berrah R., Kerroumi Y., Mimram L., Salmon D., Goulenok T., de la Selle A., Lefort A., Marmor S., Helali N.H., Zeller V., Jullien V. Clinical Microbiology and Infection. 2025 31:5 (832-838)舒更葡糖或新斯的明逆转维库溴铵诱导犬神经肌肉阻滞的速度：随机临床试验与药理学建模Speed of reversal by sugammadex or neostigmine after vecuronium-induced neuromuscular block in dogs: Randomized clinical trial and pharmacological modelingMartin-Flores M., Lorenzutti A.M., Markmann A.D., Araos J., Campoy L. Veterinary Anaesthesia and Analgesia. 2025 52:3 (328-337)阿昔洛韦及其主要代谢产物 9-羧甲氧基甲基鸟嘌呤在早期肝移植受者中的群体药代动力学及伐昔洛韦的安全性评估Population pharmacokinetics of aciclovir and its major metabolite 9-carboxymethoxymethylguanine and safety profile of valaciclovir in early liver transplant recipientsKably B., Briard M., Francoz C., Roux O., Houhou N., Mackiewicz V., Peytavin G., Durand F., Lê M.P. Journal of Antimicrobial Chemotherapy. 2025 80:5 (1302-1308)一种用于治疗慢性乙型肝炎的衣壳蛋白装配调节剂作用的多尺度模型A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B左乙拉西坦药代动力学在真实世界中的患者间变异性Real-world interpatient variability in the pharmacokinetics of levetiracetamChykharivska A., Kagan L., Wagner M., Brunetti L. Fundamental and Clinical Pharmacology. 2025 39:2 Article Number e13059接受连续性肾脏替代治疗的危重患者是否需要调整头孢洛林给药剂量？基于回顾性数据的头孢洛林PopPK模型及目标达成概率分析的剂量模拟Do Critically Ill Patients Undergoing Continuous Renal Replacement Therapy Require Ceftaroline Dosage Adjustments? Ceftaroline PopPK Model and Dosage Simulations with the Probability of Target Attainment Analysis Based on Retrospective DataAdamiszak A., Pietrzkiewicz K., Bartkowska-Śniatkowska A., Smuszkiewicz P., Kusza K., Grześkowiak E., Bienert A. Antibiotics. 2025 14:4 Article Number 347胶质母细胞瘤患者中帕米帕利总药量及游离药量的PopPK建模：药物处置机制解析与给药方案优化Population Pharmacokinetic Modeling of Total and Unbound Pamiparib in Glioblastoma Patients: Insights into Drug Disposition and Dosing OptimizationWickramasinghe C., Kim S., Jiang Y., Bao X., Yue Y., Jiang J., Hong A., Sanai N., Li J. Pharmaceutics. 2025 17:4 Article Number 524美罗培南在严重细菌感染患者中的群体药动学与基于模型的给药方案优化Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infectionMurínová I., Švidrnoch M., Gucký T., Rezáč D., Hlaváč J., Slanar O., Šíma M. European Journal of Hospital Pharmacy. 2024 31:3 (253-258)万古霉素在越南儿科患者治疗药物监测中的PopPK建模及中点浓度便捷采样Population Pharmacokinetic Modeling and Convenient Sampling of Midpoint Concentration for Therapeutic Drug Monitoring of Vancomycin in Vietnamese Pediatric PatientsHai L.B., Kien P.C., Dua N.T., Hao N.T., Hung V.M., Hai N.T., Le J., Huong N.T.L. Pharmaceutical Sciences Asia. 2024 51:3 (241-249)影响万古霉素谷浓度的因素：沙特非重症监护患者的PopPK模型Factors Affecting Vancomycin Trough Concentration; a Population Pharmacokinetic Model in Non-Critical Care Saudi PatientsOrvacabtagene Autoleucel, 一种自体 BCMA 导向的CAR-T 细胞产品在治疗复发/难治性多发性骨髓瘤患者中的PopPK研究Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple MyelomaHu H., Li Y., Piasecki J., Hosseyni D., Yan Z., Liu X., Ogasawara K., Zhou S., Cheng Y. Clinical Cancer Research. 2025 31:6 (1163-1171)建模分析表明，奈玛特韦-利托那韦治疗后出现的 SARS-CoV-2 病毒反弹，是由靶细胞得以保留与病毒清除不彻底共同导致的Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearancePhan T., Ribeiro R.M., Edelstein G.E., Boucau J., et al.Journal of Virology. 2025 99:3用于癌症药物PK-PD建模与模拟的多器官芯片Multiorgan-on-a-chip for cancer drug pharmacokinetics-pharmacodynamics (PK-PD) modeling and simulationsMohammed A.E., Kurucaovalı F., Okvur D.P. Journal of Pharmacokinetics and Pharmacodynamics. 2025 52:1 Article Number 1NX210c多肽在健康老年受试者中的安全性、耐受性及PK-PD关系研究：一项随机、安慰剂对照、双盲、多剂量递增试验Safety, Tolerability and Pharmacokinetic-Pharmacodynamic Relationship of NX210c Peptide in Healthy Elderly Volunteers: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study卡泊芬净在接受体外膜氧合治疗的危重患者中的PopPK研究——ASAP ECMO 研究Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation—an ASAP ECMO studyAbdul-Aziz M.H., Diehl A., Liu X., Cheng V., Corley A., Gilder E., Levkovich B., McGuinness S., Ordonez J., Parke R., Pellegrino V., Wallis S.C., Fraser J.F., Shekar K., Roberts J.A. Antimicrobial Agents and Chemotherapy. 2025 69:2肾功能不全患者中哌拉西林剂量调整：无论是否接受肾脏替代治疗, 均需增加达到目标暴露量Dosing of Piperacillin in Altered Renal Function with and without Renal Replacement Therapy for Required Increased ExpositionSurat G., Dohmann E., Scherf-Clavel O., Kurlbaum M., Hagel S. Open Forum Infectious Diseases2025 12 Supplement 1 (S798-)重症成人鲍曼不动杆菌感染患者口服米诺环素的PK模型Phamacokinetic Model of Oral Minocycline in Critically Ill Adult Patients with Acinetobacter baumannii InfectionKoumaki V., Athanassa Z., Valsami G., Papakyriakopoulou P., Saitani E.-M., Marques S., Manioudaki S., Sakagianni A., Dokoumatzidis A., Tsakris A. Open Forum Infectious Diseases. 2025 12 Supplement 1 (S801-)使用容积吸收微量采样法研究多器官功能障碍综合征危重患儿中的万古霉素群体药代动力学Vancomycin Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children with Multiple Organ Dysfunction SyndromeShiau J., Amajor V., Rhodes N.J., Zuppa A., Downes K.J., Takyi-Williams J., Wen B., Scheetz M.H. Open Forum Infectious Diseases. 2025 12 Supplement 1 (S788-S789)粒细胞集落刺激因子的群体PK-PD建模以优化 CD34+细胞采集的给药剂量与给药时机Population Pharmacokinetic–Pharmacodynamic Modeling of Granulocyte Colony-Stimulating Factor to Optimize Dosing and Timing for CD34+ Cell HarvestingXu Jiang, Jun Seok Cha, Byung Hak Jin, Choon Ok Kim, Dongwoo Chae. Clinical and Translational Science, 2025; 18:e70121基于PopPK模型，为接受血液透析的肥胖患者群体制定万古霉素负荷剂量个体化给药方案Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic modelPolášková L., Hartinger J.M., Murínová I., Michálek P., Slanař O., Šíma M. Journal of Chemotherapy. 2025 37:2 (121-129)考虑个体间变异的低维神经常微分方程在 Monolix 和 NONMEM 中的实现Low-dimensional neural ordinary differential equations accounting for inter-individual variability implemented in Monolix and NONMEMBräm D.S., Steiert B., Pfister M., Steffens B., Koch G. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:1 (5-16)瑞德西韦及其代谢物在健康受试者和肾功能不全患者中的药代动力学模拟Pharmacokinetic simulations for remdesivir and its metabolites in healthy subjects and patients with renal impairment群体PK/PD分析证实 SB16 与参比药物地舒单抗具有生物相似性Population pharmacokinetics/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab肠溶阿司匹林胶囊与片剂在健康受试者群体中的PK-PD研究Population Pharmacokinetic and Pharmacodynamic Modeling of Enteric-Coated Aspirin Capsule and Tablet Formulations in Healthy Subjects结核病治疗中剂量精准的重要性The importance of getting the dose right in the treatment of tuberculosis瑞舒伐他汀和依折麦布联合用药导致肠肝循环的群体PK-PD研究Population Pharmacokinetics and Pharmacodynamics with Enterohepatic Recirculation of Co-Medication of Rosuvastatin and Ezetimibe在美国未感染 HIV 的成人中单独使用抗HIV-1 单克隆抗体 PGT121.414.LS，及与VRC07-523LS 联合给药的安全性、耐受性、药代动力学及中和活性研究（项目编号HVTN 136/HPTN 092）：一项首次人体、开放标签、随机对照的 1 期临床试验Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialEdupuganti S., Hurt C.B., Stephenson K.E., Huang Y., et al.The Lancet HIV. 2025 12:1 (e13-e25)恩诺沙星在治疗肉鸡大肠杆菌病中的PK、PD预测指标及蒙特卡洛模拟研究Pharmacokinetics, pharmacodynamic efficacy prediction indices, and Monte Carlo simulations of enrofloxacin for the treatment of colibacillosis in broiler chickens卡铂在犬类中的PopPK建模及其临床剂量调整Population pharmacokinetics modelling for clinical dose adjustment of carboplatin in dogsBéguin J., Mahfoudhi S., Uzel M., Rostang A., Ibish C., Ferran A.A., Pelligand L., Hulin A., Kohlhauer M. BMC Veterinary Research. 2024 20:1 Article Number 575Development of a Population Pharmacokinetic Gabapentin Model Leveraging Therapeutic Drug Monitoring ConcentrationsAl-Zubaydi F., Wassef A., Kagan L., Brunetti L. Pharmaceutics. 2024 16:12 Article Number 1514阿莫西林对犬类假中间葡萄球菌PK-PD评价Pharmacokinetics and Pharmacodynamics Evaluation of Amoxicillin Against Staphylococcus pseudintermedius in DogsJeong J.-S., Kim J.-W., Kim J.-H., Kim C.-Y., Chung E.-H., Boo S.-Y., Lee S.-H., Ko J.-W., Kim T.-W. Pathogens. 2024 13:12 Article Number 1121膳食和制剂对耐药性发育性及癫痫性脑病患儿体内大麻二酚全身暴露的影响Impact of food and formulation on cannabidiol systemic exposure in children with drug-resistant developmental and epileptic encephalopathiesBrstilo L., Reyes G., Ibarra M., Cáceres Guido P., Bressan I., Marin M.N., Delaven S.F., Agostini S., Pérez Montilla C., López M.E., Cresta A., García Bournissen F., Schaiquevich P., Caraballo R. Epilepsia. 2024 65 Supplement 1 (492-)基于模型荟萃分析建立复方口服避孕药突破性出血模型Development of breakthrough bleeding model of combined-oral contraceptives utilizing model-based meta-analysisChen H., Chun D., Lingineni K., Guzy S., Cristofoletti R., Hoechel J., Jiao T., Cicali B., Vozmediano V., Schmidt S. CPT: Pharmacometrics and Systems Pharmacology. 2024 13:11 (2016-2025)静脉注射免疫球蛋白在治疗各类免疫系统疾病患者中的PopPK模型Population Pharmacokinetic Model of Intravenous Immunoglobulin in Patients Treated for Various Immune System DisordersLee J.L., Mohamed Shah N., Makmor-Bakry M., Islahudin F., Alias H., Mohd Saffian S. Clinical Therapeutics. 2024 46:12 (e25-e37)持续输注哌拉西林/他唑巴坦可优化择期盆腔摘除术患者术中抗生素暴露水平Continuous infusion of piperacillin/tazobactam optimizes intraoperative antibiotic exposure in patients undergoing elective pelvic exenteration surgeryJackson D., Ulldemolins M., Liu X., Harris C., Tognolini A., Wallis S.C., Sumi C., Parker S.L., Eley V., Roberts J.A. Antimicrobial Agents and Chemotherapy. 2024 68:12接受单倍体相合干细胞移植并采用移植后环磷酰胺/环孢素 A 为基础的移植物抗宿主病预防方案的患者中，霉酚酸暴露量降低—需加强剂量调整Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis - Need for Dose IntensificationPai A.A., Panetta J.C., Bijukumar N., Renji R.M., A M., Jayaraman A., Karumathil S., Korula A., Selvarajan S., Srivastava A., Abraham A., Mathews V., George B., Kulkarni U., Balasubramanian P. Blood. 2024 144 Supplement 1 (2150-)不同剂量的甲氨蝶呤在类风湿关节炎患者中的PK-PD建模与模拟Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis研究丙泊酚作为单一药物对 2-12 岁儿童双频谱指数峰值效应时间的影响Understanding time to peak effect of propofol as sole agent on bispectral index in children aged 2–12 yearsGavel G., Koch G., Terrier A., Atkinson A., Pfister M., Erb T. Paediatric Anaesthesia. 2024 34:10 (1019-1028)替扎帕林（一种皮下注射普通肝素的替代药物）用于重度及终末期肾功能不全患者的回顾性单中心观察性研究Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study麦考酚酸酯在印度狼疮性肾炎患者群体中的PopPK及有限采样策略研究Population Pharmacokinetics and Limited Sampling Strategy of Mycophenolate Mofetil for Indian Patients With Lupus NephritisKoloskoff K., Panwar R., Rathi M., Mathew S., Sharma A., Marquet P., Benito S., Woillard J.-B., Pattanaik S. Therapeutic Drug Monitoring. 2024 46:5 (567-574)通过建模与模拟确定儿科重症监护室中美罗培南的最佳给药策略Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation给药剂量是否得当？重症儿童患者中头孢吡肟的PopPK研究Are We Dosing Correctly? Population Pharmacokinetics of Cefepime in Critically Ill Pediatric PatientsRolsma S., Blackman M., Beck C., Dbouk A., Morovia F., Glover F., Ess G., Dohler K., Bridges B., Choi L., Creech C.B. Journal of the Pediatric Infectious Diseases Society. 2024 13 Supplement 4 (S9-S10)评估高加索健康受试者中与体重相关的协变量对利福平PK的影响Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteersBilal M., Ullah S., Jaehde U., Trueck C., Zaremba D., Wachall B., Wargenau M., Scheidel B., Wiesen M.H.J., Gazzaz M., Chen C., Büsker S., Fuhr U., Taubert M., Dokos C. European Journal of Clinical Pharmacology. 2024 80:9 (1271-1283)采用非线性混合效应模型对肥胖血液透析患者庆大霉素个体药代动力学参数进行估算Individual pharmacokinetic parameter estimation of gentamicin in an obese hemodialysis patient using non-linear mixed effect modelLee H., Yoon S., Chung J.Y. Translational and Clinical Pharmacology. 2024 32:3 (150-158)利用定量药理学评估患者友好的伊维菌素 CHILD-IVITAB 在体重≥15 kg 和 <15 kg 儿童中的给药剂量Pharmacometrics to Evaluate Dosing of the Patient-Friendly Ivermectin CHILD-IVITAB in Children ≥ 15 kg and <15 kgGolhen K., Buettcher M., Huwyler J., van den Anker J., Gotta V., Dao K., Rothuizen L.E., Kobylinski K., Pfister M. Pharmaceutics. 2024 16:9 Article Number 1186Elexacaftor/tezacaftor/ivacaftor 药代动力学与 2 至 5 岁儿童行为障碍的发生情况的研究Elexacaftor/tezacaftor/ivacaftor pharmacokinetics and occurance of behavioral disorders in children aged 2 to 5Truong N., Benaboud S., Chouchana L., Bonnel A., Barboura M., Bouazza N., Gautier S., Rouillon S., Froelicher-Bournaud L., Bihouee T., Bui S., Treluyer J., Sermet-Gaudelus I., Foissac F. Journal of Cystic Fibrosis. 2024 23 Supplement 2 (S277-S278)重症患者需增加头孢哌酮负荷剂量：一项采用PK建模评估推荐负荷剂量的回顾性研究Loading Dose of Ceftazidime Needs to Be Increased in Critically Ill Patients: A Retrospective Study to Evaluate Recommended Loading Dose with Pharmacokinetic ModellingLaunay M., Ollier E., Kably B., Le Louedec F., Thiery G., Lanoiselée J., Perinel-Ragey S. Antibiotics. 2024 13:8 Article Number 756达沙替尼在健康受试者中的PopPK研究Population Pharmacokinetics of Dasatinib in Healthy SubjectsHassouneh W.B., Al-Ghazawi M.A., Saleh M.I., Najib N. Pharmaceuticals. 2024 17:6 Article Number 671WS15.03 Elexacaftor/tezacaftor/ivacaftor 在囊性纤维化儿科患者中的PopPK研究WS15.03 Elexacaftor/tezacaftor/ivacaftor population pharmacokinetics in paediatric patients with cystic fibrosisTruong N.H., Benaboud S., Bardin E., et al. Journal of Cystic Fibrosis. 2024 23 Supplement 1 (S28-)慢性髓性白血病患者体重指数与血浆中伊马替尼浓度的关系，并采用PK引导的给药策略减轻其临床影响Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategyMaroselli P., Fanciullino R., Colle J., Farnault L., Rocher P., Venton G., Costello R., Ciccolini J. Journal of Clinical Oncology. 2024 42:16 Supplement延长纳武利尤单抗给药间隔：在未筛选癌症患者中开展基于模型的模拟Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patientsPuszkiel A., Bianconi G., Pasquiers B., Balakirouchenane D., Arrondeau J., Boudou-Rouquette P., Bretagne M.-C., Salem J.-E., Declèves X., Vidal M., Kramkimel N., Guegan S., Aractingi S., Huillard O., Alexandre J., Wislez M., Goldwasser F., Blanchet B. British Journal of Cancer. 2024 130:11 (1866-1874)RPEM：随机蒙特卡洛参数期望最大化算法RPEM: Randomized Monte Carlo parametric expectation maximization algorithmChen R., Schumitzky A., Kryshchenko A., Nieforth K., Tomashevskiy M., Hu S., Garreau R., Otalvaro J., Yamada W., Neely M.N. CPT: Pharmacometrics and Systems Pharmacology. 2024 13:5 (759-780)肺移植受者进行伊沙康唑治疗药物监测的理论依据The Rationale for Therapeutic Drug Monitoring of Isavuconazole in a Lung Transplant RecipientZajacova A., Sima M., Havlin J., Klapkova E., Lischke R., Slanar O., Dvorackova E. Journal of Heart and Lung Transplantation. 2024 43:4 Supplement (S644-S645)Lumacaftor/Ivacaftor 在囊性纤维化儿科患者中的PopPK：迈向个体化治疗的第一步Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized TherapyBouazza N., Urien S., Foissac F., Choupeaux L., et al. Clinical Pharmacokinetics. 2024 63:3 (333-342)赖诺普利在高血压的儿童和正常至轻度肾功能受损的青少年的PopPK研究Population pharmacokinetics of lisinopril in hypertensive children and adolescents with normal to mildly reduced kidney functionSandra L., Degraeuwe E., De Bruyne P., De Baere S., Croubels S., Van Bocxlaer J.F.P., Raes A., Vande Walle J., Gasthuys E., Vermeulen A. British Journal of Clinical Pharmacology. 2024 90:2 (504-515)基于模型的临床前试验心血管安全性评估与转化教程A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trialsKulesh V., Vasyutin I., Volkova A., Peskov K., Kimko H., Sokolov V., Alluri R. CPT: Pharmacometrics and Systems Pharmacology2024 13:1 (5-22)提高奥拉帕利的药物暴露量以优化不良反应管理Improving olaparib exposure to optimize adverse effects managementSterlé M., Puszkiel A., Burlot C., Pereira E., Bellesoeur A., De Percin S., Beinse G., Fumet J.-D., Favier L., Niogret J., Blanchet B., Royer B., Bengrine-Lefevre L., Schmitt A. Therapeutic Advances in Medical Oncology. 2024 16疑似急性肾移植排斥反应：甲基泼尼松龙治疗下他克莫司的药代动力学研究Suspicious of Acute Kidney Graft Rejection: Tacrolimus Pharmacokinetics Under Methylprednisolone TherapyBidu N.S., Mattoso R.J.C., Santos O.A.C.O., Alves I.A., Fernandes B.J.D., Couto R.D. Current Drug Research Reviews. 2024 16:3 (403-411)►►►往年MonolixSuite文献汇总返回搜狐，查看更多
2026-02-06
Journal of Antimicrobial Chemotherapy Volume 81, Issue 1抗菌化疗杂志81卷 1期
https://academic.oup.com/jac/issue
50th Anniversary Collection
50周年纪念合集
Review（综述）
1
Artificial intelligence for improving decision-making in bacterial infection management: a narrative review
人工智能在改善细菌感染治疗决策中的应用：一项叙述性综述
Anisia Talianu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf470, https://doi.org/10.1093/jac/dkaf470
Reviews（综述）
2
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America
耐甲氧西林中间型葡萄球菌的演变格局：欧洲、亚洲和北美洲新流行浪潮的出现
Lillian Rose Giarratana and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf340, https://doi.org/10.1093/jac/dkaf340
3
Azithromycin resistance in non-typhoidal Salmonella: a review
非伤寒沙门氏菌对阿奇霉素的耐药性：综述
Zhe Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf341, https://doi.org/10.1093/jac/dkaf341
4
Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications
抗生素药效动力学：从最低抑菌浓度到高级指标及其应用
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf374, https://doi.org/10.1093/jac/dkaf374
5
Progress in the study of drug resistance mechanism of Bacillus cereus
蜡样芽孢杆菌耐药机制研究进展
Yuhang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf399, https://doi.org/10.1093/jac/dkaf399
6
The curious constraints on clofazimine
氯法齐明的奇特限制
Maple Goh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf430, https://doi.org/10.1093/jac/dkaf430
7
Antiplasmid systems: a novel strategy to combat antibiotic resistance
抗质粒系统：对抗抗生素耐药性的新策略
Mohd Asim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf472, https://doi.org/10.1093/jac/dkaf472
Systematic Review（系统综述）
8
Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes
欧洲球孢子菌病：流行病学、治疗和预后的系统文献综述
Priya Shastri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf407, https://doi.org/10.1093/jac/dkaf407
9
Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method
用标准方法分析小鼠大腿和空心纤维剂量分次研究中的抗菌药物药代动力学/药效动力学指数的系统综述
Najla Alabdulkarim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf446, https://doi.org/10.1093/jac/dkaf446
Virtual Roundtable（虚拟圆桌会议）
10
Procalcitonin in the management of lower respiratory tract infection and sepsis
降钙素原在下呼吸道感染和败血症治疗中的应用
Ramy H Elshaboury and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf298, https://doi.org/10.1093/jac/dkaf298
Original Research（论著）
11
Model-based assessment of letermovir pharmacokinetics in allogeneic haematopoietic stem cell transplant recipients
来特莫韦在异基因造血干细胞移植受者中药代动力学的基于模型的评估
Chrisoula Tahtsidou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf427, https://doi.org/10.1093/jac/dkaf427
12
In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis
体外试验评估依拉环素（CF-301）对甲氧西林敏感或甲氧西林耐药金黄色葡萄球菌及凝固酶阴性葡萄球菌（从感染性心内膜炎患者中分离）的活性
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf435, https://doi.org/10.1093/jac/dkaf435
13
Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study
评估皮下注射阿莫西林/克拉维酸药代动力学作为老年患者静脉给药替代方案——PhASAge研究
Nicolas Grégoire and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf381, https://doi.org/10.1093/jac/dkaf381
14
Real-life use of isavuconazole in Spanish children and adolescents
西班牙儿童和青少年中艾沙康唑的实际使用情况
Natalia Mendoza-Palomar and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf394, https://doi.org/10.1093/jac/dkaf394
15
No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis
基于FAERS数据库的不成比例性分析：未发现甘氨酰环素类与颅内高压相关的药物警戒信号
Slobodan M Jankovic and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf395, https://doi.org/10.1093/jac/dkaf395
16
Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet
成人经肠内营养管给予泊沙康唑：口服混悬液与碾碎的缓释片的药代动力学目标达成情况比较
Nirjan Bhattarai and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf396, https://doi.org/10.1093/jac/dkaf396
17
Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies
CYP3A4介导的药物相互作用特征：一项关于泊沙康唑和鲁索替尼在血液系统恶性肿瘤中的固定序列药代动力学中国研究
Beibei Liang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf398, https://doi.org/10.1093/jac/dkaf398
18
Differences in prescription for impetigo and cellulitis across years in three European countries
三个欧洲国家不同年份脓疱病和蜂窝织炎的处方差异
Thomas Bettuzzi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf400, https://doi.org/10.1093/jac/dkaf400
19
β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit
重症监护室社区获得性脓毒症早期阶段监测的β-内酰胺浓度
Karolina Liljedahl Prytz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf401, https://doi.org/10.1093/jac/dkaf401
20
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
在空心纤维系统中，模拟吸入氯法齐明与口服氯法齐明联合阿奇霉素和乙胺丁醇的抗结核分枝杆菌疗效增强比较
Jelmer Raaijmakers and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf402, https://doi.org/10.1093/jac/dkaf402
21
Identification of antimicrobial resistance genes in Escherichia coli through network diffusion
通过网络扩散法鉴定大肠杆菌中的抗生素耐药基因
Anis Mansouri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf404, https://doi.org/10.1093/jac/dkaf404
22
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease
依培硼罗在脓肿分枝杆菌肺病空心纤维系统模型中的临床前评估
Sanjay Singh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf405, https://doi.org/10.1093/jac/dkaf405
23
The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization
β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度（MICcBLI）作为评估哌拉西林/他唑巴坦药代动力学/药效动力学关系以优化给药的方法
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf406, https://doi.org/10.1093/jac/dkaf406
24
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction
解析铜绿假单胞菌AmpC诱导过程中青霉素结合蛋白、β-内酰胺酶活性和mRNA动态的三元关系
Maria Montaner and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf408, https://doi.org/10.1093/jac/dkaf408
25
Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge
不同地区万古霉素可变型粪肠球菌菌株中线性VanA质粒的未被察觉的传播：一项诊断挑战
Ana C Almeida-Santos and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf409, https://doi.org/10.1093/jac/dkaf409
26
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study
在病毒学抑制的HIV感染者中从依曲韦林切换至多拉韦林：法国多中心SWEED观察性研究的结果
Romain Palich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf410, https://doi.org/10.1093/jac/dkaf410
27
HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda
乌干达多替拉韦时代孕产妇及哺乳期母亲中HIV-1耐药情况及其与儿童HIV感染的关联
Anne Kapaata and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf411, https://doi.org/10.1093/jac/dkaf411
28
Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States
美国威斯康星州农村地区高风险成人因呼吸道合胞病毒、流感或人偏肺病毒感染就诊时的门诊抗生素处方情况
Sarah C J Jorgensen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf412, https://doi.org/10.1093/jac/dkaf412
29
Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies
奥马环素作为鸟分枝杆菌感染候选药物：单药及联合治疗的体外研究
Saskia E Mudde and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf413, https://doi.org/10.1093/jac/dkaf413
30
Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022–2023)
后疫情时代美国成人侵袭性与非侵袭性肺炎链球菌病血清型流行病学及抗生素敏感性趋势（2022-2023）
Mekki F Bensaci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf414, https://doi.org/10.1093/jac/dkaf414
31
Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions
慢性恰加斯病患者苯芴醇药代动力学：与人口统计学因素及药物不良反应的关联
Gabriel P E Silveira and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf416, https://doi.org/10.1093/jac/dkaf416
32
Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis
博德特氏菌属中获得的抗菌药物耐药基因：全球基因组分析
Biao Tang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf418, https://doi.org/10.1093/jac/dkaf418
33
Machine learning for personalized antimicrobial susceptibility breakpoints: (Adaptive clinical breakpoint interpretation)
基于机器学习的个性化抗菌药物敏感性折点制定（自适应临床折点解释）
Yinzheng Zhong and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf419, https://doi.org/10.1093/jac/dkaf419
34
Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights
印度异常威克汉姆酵母菌血症的多中心研究：新发耐药性及机制洞察
Shristi Verma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf420, https://doi.org/10.1093/jac/dkaf420
35
Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations
减少氨曲南/阿维巴坦浪费：蒙特卡洛模拟的启示
Yeleen Fromage and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf421, https://doi.org/10.1093/jac/dkaf421
36
Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates
基于纳米颗粒的环丙沙星与美罗培南共递送可增强对多重耐药高毒力肺炎克雷伯菌临床分离株的协同活性
Reham Mostafa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf422, https://doi.org/10.1093/jac/dkaf422
37
Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing
危重症儿童及青年总游离哌拉西林群体药代动力学模型开发：用于蒙特卡洛模拟及模型引导的精准给药
Sonya Tang Girdwood and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf423, https://doi.org/10.1093/jac/dkaf423
38
Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients
达标分析：住院患者达到目标万古霉素血浆浓度所需的时间与剂量
W Töpfer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf424, https://doi.org/10.1093/jac/dkaf424
39
Notable transmitted HIV drug resistance among people who inject drugs in Pakistan
巴基斯坦注射毒品人群中显著传播的HIV耐药性
Stephanie Melnychuk and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf425, https://doi.org/10.1093/jac/dkaf425
40
Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium
协同但临床难以实现：阿莫西林/头孢曲松联合对氨苄西林敏感粪肠球菌的体外活性
Ahmed Ashrin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf426, https://doi.org/10.1093/jac/dkaf426
41
Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase–producing Gram-negative bacteria in a neutropenic murine thigh infection model
中性粒细胞减少小鼠大腿感染模型中他尼硼巴坦（VNRX-5133）联合头孢吡肟对产β-内酰胺酶革兰氏阴性菌的药效动力学研究
Panagiota-Christina Georgiou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf431, https://doi.org/10.1093/jac/dkaf431
42
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.
非塞拉蒂亚属肠杆菌目细菌所致心内膜炎的流行病学及治疗
Clayton F Hausberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf432, https://doi.org/10.1093/jac/dkaf432
43
Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus
阿普拉霉素及其组合对脓肿分枝杆菌的增强活性
Yanqin Huang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf433, https://doi.org/10.1093/jac/dkaf433
44
Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene
印度毛癣菌与红色毛癣菌中由ABC转运蛋白和MFS基因介导的流出泵型多重耐药机制
Dipika Shaw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf434, https://doi.org/10.1093/jac/dkaf434
45
Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases
鞘氨醇杆菌属作为SPI Ambler B类金属β-内酰胺酶的固有产生者
Delphine Girlich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf436, https://doi.org/10.1093/jac/dkaf436
46
Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli
blaNDM-1阳性碳青霉烯耐药溶胶阿卡净菌的全球系统发育地理学及基因组特征
Pengpeng Min and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf437, https://doi.org/10.1093/jac/dkaf437
47
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients
血液透析患者潜伏性结核治疗中每月一次每日利福喷丁的药代动力学及耐受性
Thornthun Ueaphongsukkit and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf439, https://doi.org/10.1093/jac/dkaf439
48
In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales
头孢吡肟-恩美他唑巴坦、头孢吡肟-他尼硼巴坦及头孢吡肟-齐德巴坦对产碳青霉烯酶肠杆菌目的体外敏感性
Marion Dutkiewicz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf440, https://doi.org/10.1093/jac/dkaf440
49
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates
舒巴坦/杜洛巴坦联合β-内酰胺类抗生素对澳大利亚脓肿分枝杆菌分离株的体外疗效
Kirby Patterson-Fahy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf441, https://doi.org/10.1093/jac/dkaf441
50
Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate
利用CRISPR-Cas9及CRISPRi系统逆转临床多重耐药大肠杆菌分离株的抗生素耐药性
Ruonan Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf442, https://doi.org/10.1093/jac/dkaf442
51
Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?
重症监护室中复方磺胺甲噁唑的应用：固定组合在现实中的不可行性？
Manon Launay and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf443, https://doi.org/10.1093/jac/dkaf443
52
National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
哥伦比亚全国代表性调查：基于下一代测序的抗逆转录病毒耐药相关突变分析
Ernesto Martínez-Buitrago and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf444, https://doi.org/10.1093/jac/dkaf444
53
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens
基于模型的含固定剂量多替拉韦方案减量策略比较
Laura Dickinson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf445, https://doi.org/10.1093/jac/dkaf445
54
Therapeutic drug monitoring and target attainment of unbound flucloxacillin in hospitalized patients with measured MICs (FLUTE)
住院患者中游离氟氯西林的治疗药物监测及目标达成情况（基于实测最低抑菌浓度的FLUTE研究）
Pjotr P Temme and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf447, https://doi.org/10.1093/jac/dkaf447
55
Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes
奈玛特韦/利托那韦纳入急症治疗目录：一项多中心回顾性评估定量经济与定性临床结果的研究
Jose Valdes Ledesma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf448, https://doi.org/10.1093/jac/dkaf448
56
Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study
采用批量质量保证抽样法对养老院进行本地抗生素耐药性监测的可行性研究
Sacha Kuil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf451, https://doi.org/10.1093/jac/dkaf451
57
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24
2021-2024年，在世卫组织三个区域的八个世卫组织增强淋球菌抗菌药物监测计划国家中，新型抗菌药物吉皮达星对淋病奈瑟菌分离株的体外活性较高
Josefine Ahlstrand and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf452, https://doi.org/10.1093/jac/dkaf452
58
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable
尽管整合酶抑制剂用于治疗HIV感染的使用量不断增加，但此类药物的耐药性仍保持稳定
Cathia Soulie and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf454, https://doi.org/10.1093/jac/dkaf454
59
Fine-needle aspiration in infected necrotizing pancreatitis in the delayed intervention era: a post hoc analysis of safety, microbiological yield and therapeutic implications
延迟干预时代感染性坏死性胰腺炎的细针穿刺抽吸术：安全性、微生物学检出率及治疗意义的事后分析
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf455, https://doi.org/10.1093/jac/dkaf455
60
β-Lactam dosing in critically ill children: predictors for target non-attainment
危重症儿童β-内酰胺类药物给药：未达目标浓度的预测因素
Stef Schouwenburg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf457, https://doi.org/10.1093/jac/dkaf457
61
Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis
实体器官移植患者合并侵袭性曲霉病住院时三唑类药物与钙调磷酸酶抑制剂或哺乳动物雷帕霉素靶蛋白抑制剂的联合用药情况
Barbara Alexander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf461, https://doi.org/10.1093/jac/dkaf461
62
In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes
携带最常见碳青霉烯酶基因的鲍曼不动杆菌中头孢地尔耐药突变体的体外筛选
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf462, https://doi.org/10.1093/jac/dkaf462
63
Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input
预防产OXA β-内酰胺酶铜绿假单胞菌感染耐药性的产生：将临床结局与中空纤维模型输入相关联
María M Montero and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf464, https://doi.org/10.1093/jac/dkaf464
64
A national pilot community pharmacy–led urinary tract infection service: clinical and patient-reported outcomes from 9077 consultations
全国社区药房主导的尿路感染服务试点项目：9077次咨询的临床结局和患者报告结局
Efi Mantzourani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf466, https://doi.org/10.1093/jac/dkaf466
65
Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus
提高转化价值：针对活跃增殖、营养匮乏和生物膜包裹的脓肿分枝杆菌进行临床前药物活性测试
Henriëtte M Meliefste and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf468, https://doi.org/10.1093/jac/dkaf468
Research Letters（研究快报）
66
Novel multiresistance transposon Tn7731 in bovine Pasteurella multocida from Germany
德国牛源多杀性巴氏杆菌中新型多重耐药转座子Tn7731
Henrike Krüger-Haker and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf336, https://doi.org/10.1093/jac/dkaf336
67
Efficacy of eravacycline in difficult-to-treat (DTR) Acinetobacter baumannii bacteraemia in ICU: a case report
厄他培南治疗重症监护病房难治性鲍曼不动杆菌菌血症的疗效：一例病例报告
Monica Melchio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf347, https://doi.org/10.1093/jac/dkaf347
68
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
来特莫韦暴露的造血细胞移植受者中EB病毒感染和移植后淋巴增殖性疾病风险可能增加
Jose F Camargo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf348, https://doi.org/10.1093/jac/dkaf348
69
Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring
达巴万星在严重体重不足人工瓣膜心内膜炎女性患者中的给药：主动治疗药物监测的关键作用
Ambra Barco and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf365, https://doi.org/10.1093/jac/dkaf365
70
Cefazolin-induced seizures in a haemodialysis patient with elevated serum and cerebrospinal fluid concentrations: a case report
血液透析患者头孢唑林血清和脑脊液浓度升高诱发癫痫：一例病例报告
Kohei Hasegawa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf373, https://doi.org/10.1093/jac/dkaf373
71
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
使用聚丙烯腈膜进行连续性肾脏替代治疗的患者中卡泊芬净药代动力学治疗监测的回顾性分析
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf390, https://doi.org/10.1093/jac/dkaf390
72
Diffusion of OXA-48- and NDM-5-producing Klebsiella pneumoniae ST383 clone in Central Italy
产OXA-48和NDM-5的肺炎克雷伯菌ST383克隆在意大利中部的传播
Gloria D’Achille and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf397, https://doi.org/10.1093/jac/dkaf397
73
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry
来那卡帕韦在病毒载量阳性且接受过大量抗逆转录病毒治疗的HIV感染者中的持久性：来自PRESTIGIO登记处的现实数据
Tommaso Clemente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf415, https://doi.org/10.1093/jac/dkaf415
74
Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker
猪场工人利奈唑胺耐药猪鼻支原体分离株中噁唑烷酮类耐药基因cfr和optrA的共携带情况
Gi Yong Lee and Soo-Jin Yang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf428, https://doi.org/10.1093/jac/dkaf428
75
Importance of reviewing the package insert from gradient strip manufacturers
梯度扩散法药敏纸片生产商说明书审阅的重要性
Mandy Wootton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf429, https://doi.org/10.1093/jac/dkaf429
76
One resistance gene, many transposons: repeated formation of compound and pseudo-compound transposons carrying the aphA1 kanamycin and neomycin resistance gene
一个耐药基因，多个转座子：携带aphA1卡那霉素和新霉素耐药基因的复合及假复合转座子的重复形成
Christopher J Harmer and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf450, https://doi.org/10.1093/jac/dkaf450
77
Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis
接受暴露后多西环素预防性治疗的暴露前预防用药男男性行为者中未发现性病淋巴肉芽肿
Cristina Gómez-Ayerbe and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf456, https://doi.org/10.1093/jac/dkaf456
78
In vitro activity of gepotidacin against Chlamydia trachomatis
吉皮达星对沙眼衣原体的体外活性
Arabella Touati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf460, https://doi.org/10.1093/jac/dkaf460
Journal of Antimicrobial Chemotherapy Volume 81, Issue 2抗菌化疗杂志 81卷 2期
https://academic.oup.com/jac/issue
Viewpoints（观点）
1
Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
长效糖肽类：最需要它们的患者获取药物的障碍有哪些，如何克服？
Aleece MacPhail and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf471, https://doi.org/10.1093/jac/dkaf471
2
Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies
靶向治疗时代急性白血病抗真菌预防的重新定义
Marcio Nucci and Johan Maertens
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag010, https://doi.org/10.1093/jac/dkag010
Reviews（综述）
3
Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae
替加环素对肺炎克雷伯菌的耐药机制及临床疗效研究进展
Meilin Wu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf504, https://doi.org/10.1093/jac/dkaf504
4
Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations
两性霉素B脂质体与肾脏安全性：证据回顾及临床考量
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf473, https://doi.org/10.1093/jac/dkaf473
5
Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era
奥密克戎时代减轻血液系统恶性肿瘤患者严重新冠肺炎的策略
Keiji Okinaka and Joshua T Schiffer
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf489, https://doi.org/10.1093/jac/dkaf489
Systematic Reviews（系统综述）
6
Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis
吉泊替达辛治疗尿路感染的安全性和有效性：一项基于GRADE评估的系统综述和荟萃分析
Taha Ibrahim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf469, https://doi.org/10.1093/jac/dkaf469
7
The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review
产吲哚金黄杆菌日益凸显的临床相关性和抗菌药物耐药性：一项系统综述
Bruna Abdul Ahad Saad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf476, https://doi.org/10.1093/jac/dkaf476
8
A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae
决定肺炎克雷伯菌多粘菌素耐药性的突变谱综合分析
Sambit Kumar Dwibedy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf503, https://doi.org/10.1093/jac/dkaf503
9
Factors promoting or hindering self-administered outpatient parenteral antimicrobial therapy: a systematic literature review
促进或阻碍自我给药门诊静脉注射抗菌药物治疗的因素：一项系统文献综述
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf490, https://doi.org/10.1093/jac/dkaf490
Original Research（论著）
10
Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics
头孢吡肟/恩美唑巴坦治疗革兰氏阴性假体周围关节感染？一项关于猪的靶组织药代动力学的随机研究
M B D Nielsen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf487, https://doi.org/10.1093/jac/dkaf487
11
Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients
体外膜肺氧合模式对危重患者伏立康唑暴露的影响
Xinrui Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf501, https://doi.org/10.1093/jac/dkaf501
12
Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
基于模型通过成人和婴儿群体药代动力学-药效学模型评估VRC07-523LS在婴儿中的给药方案
Dustin Huynh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf449, https://doi.org/10.1093/jac/dkaf449
13
Antibiotic resistance of Pseudomonas aeruginosa strains—intracellular metabolomics analysis
铜绿假单胞菌菌株的抗生素耐药性——细胞内代谢组学分析
Karolina Anna Mielko-Niziałek and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf453, https://doi.org/10.1093/jac/dkaf453
14
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates
头孢吡肟/齐多巴坦对舒巴坦/杜洛巴坦敏感和耐药鲍曼不动杆菌临床分离株的体外活性
Carlo Tascini and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf467, https://doi.org/10.1093/jac/dkaf467
15
Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands
荷兰肺炎支原体大环内酯类抗生素耐药性的流行情况
Patrick D J Sturm and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf475, https://doi.org/10.1093/jac/dkaf475
16
Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant
Acinetobacter baumannii
模拟肺炎患者肺部暴露情况以评估临床替加环素方案对碳青霉烯类耐药鲍曼不动杆菌的抗菌能力和耐药抑制作用
Xiaonan Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf477, https://doi.org/10.1093/jac/dkaf477
17
Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case
加拿大发现携带vanA、optrA和cfr(D)的粪肠球菌线性质粒：一项CANWARD监测病例
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf478, https://doi.org/10.1093/jac/dkaf478
18
The effect of intrauterine exposure to aminoglycosides on neonatal hearing
宫内暴露于氨基糖苷类抗生素对新生儿听力的影响
Daniel Leshin-Carmel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf483, https://doi.org/10.1093/jac/dkaf483
19
Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies
头孢他啶/阿维巴坦：对抗多重耐药铜绿假单胞菌的有力武器——揭示体内外策略
Jiaju Zhuo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf495, https://doi.org/10.1093/jac/dkaf495
20
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints
采用中国CAST折点，比较422株金黄色葡萄球菌对依拉环素的纸片扩散法、最低抑菌浓度测试条法和肉汤微量稀释法的敏感性测试结果
Xinying Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf502, https://doi.org/10.1093/jac/dkaf502
21
Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis
肺炎链球菌性脑膜炎期间达托霉素在脑脊液中的渗透情况
Pascal Chavanet and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf474, https://doi.org/10.1093/jac/dkaf474
22
Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi
用于检测广泛耐药伤寒沙门菌的快速分子诊断技术
Emma L Sweeney and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf481, https://doi.org/10.1093/jac/dkaf481
23
Gender inequality and antibiotic consumption: analysis of pharmaceutical sales data from 70 countries, 2000–22
性别不平等与抗生素消费：基于2000 - 2022年70个国家药品销售数据的分析
Deepshikha Batheja and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag002, https://doi.org/10.1093/jac/dkag002
24
Real-world evaluation of isavuconazole in children with cancer
伊沙康唑在儿童癌症患者中的现实应用评估
Janine Nijhuis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf485, https://doi.org/10.1093/jac/dkaf485
25
Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study
加纳提供细菌学服务的实验室对抗菌药物敏感性试验指南依从性的评估：一项试点研究
Joseph Elikem Efui Acolatse and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag003, https://doi.org/10.1093/jac/dkag003
26
Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan
台湾地区基于多替拉韦或比克替拉韦的抗逆转录病毒治疗失败后，HIV感染者对第二代整合酶抑制剂的耐药性
Guan-Jhou Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf488, https://doi.org/10.1093/jac/dkaf488
27
In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates
吉泊西汀对一组具有挑战性的多重耐药淋病奈瑟菌分离株的体外活性
Michelle Jayne Cole and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag001, https://doi.org/10.1093/jac/dkag001
28
A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database
基于美国食品药品监督管理局（FDA）不良事件报告系统数据库的奥马环素相关不良事件比例失衡分析
Ye-Lei Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag006, https://doi.org/10.1093/jac/dkag006
29
Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
基于体重范围的口服异速缩放米替福新给药方案在儿童内脏利什曼病患者中的简化应用
Andres Mazariegos Herrera and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag014, https://doi.org/10.1093/jac/dkag014
30
evelopment of a capability framework for antimicrobial stewardship specialist health professionals working in the NHS in England: utilizing Delphi methodology
运用德尔菲法为在英国国家医疗服务体系（NHS）中工作的抗菌药物管理专业人员制定能力框架
Ryan A Hamilton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf438, https://doi.org/10.1093/jac/dkaf438
31
First characterization of insertions in the HIV-1 integrase-coding region from people with HIV
首次对来自艾滋病病毒感染者的HIV-1整合酶编码区插入情况进行特征分析
Nhat Quang Tu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf491, https://doi.org/10.1093/jac/dkaf491
32
Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae
开发一种基于阻抗的淋病奈瑟菌快速抗菌药物敏感性检测方法
Caitlin N Daniels and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf493, https://doi.org/10.1093/jac/dkaf493
33
Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats
新型抗疟候选药物Zintrodiazine在Wistar大鼠中的幼年毒性和发育安全性研究
Hitesh A Kadu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag008, https://doi.org/10.1093/jac/dkag008
34
Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents
欧洲抗微生物药物敏感性试验委员会（EUCAST）重新定义的敏感性分类是否需要调整儿童抗生素剂量？——对四种常用药物的实用生理药代动力学建模研究
Marika A de Hoop-Sommen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf463, https://doi.org/10.1093/jac/dkaf463
35
Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study
门诊抗菌治疗（OPAT）服务中开展治疗药物监测（TDM）和精准剂量抗菌治疗的机遇：一项前瞻性观察研究
R C Wilson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf484, https://doi.org/10.1093/jac/dkaf484
36
Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy
性别、年龄和身体成分对接受长效注射用抗逆转录病毒治疗的HIV感染者利匹韦林和卡博特韦谷浓度的影响
Maria Vittoria Cossu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag024, https://doi.org/10.1093/jac/dkag024
37
Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock
头孢地尔在两例感染性休克患者长时间间歇性肾脏替代治疗期间的药代动力学
Julius J Schmidt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf496, https://doi.org/10.1093/jac/dkaf496
38
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
了解铜绿假单胞菌pvdS和fecI突变体对头孢地尔敏感性降低的机制
Yoshinori Yamano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag004, https://doi.org/10.1093/jac/dkag004
39
Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD
基于生物标志物的美罗培南在儿童重症肺炎中的生理药动学模型构建：对靶部位药代动力学/药效学的影响
Yao Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf500, https://doi.org/10.1093/jac/dkaf500
40
Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia
评估接受头孢唑林或抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症患者中，与血液延迟灭菌相关的低白蛋白血症阈值
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf498, https://doi.org/10.1093/jac/dkaf498
Research Letters（研究快讯）
41
False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report
不当使用暴露后预防用药导致第四代HIV筛查试验p24抗原弱检出后出现假阴性结果：一例病例报告
J Kimmerlin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf459, https://doi.org/10.1093/jac/dkaf459
42
Proposal for the nomenclature of tmexCD-toprJ-like gene clusters
关于tmexCD-toprJ样基因簇命名的建议
Chengzhen Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf482, https://doi.org/10.1093/jac/dkaf482
43
IS26-mediated chromosomal integration of virulence plasmid fragments in ST2237 carbapenem-resistant Klebsiella pneumoniae
IS26介导的毒力质粒片段在ST2237型碳青霉烯耐药肺炎克雷伯菌染色体中的整合
Yan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag018, https://doi.org/10.1093/jac/dkag018
Letter to the Editor（致编辑的信）
44
Comment on: Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
对“采用聚丙烯腈膜对接受连续性肾脏替代治疗的患者进行卡泊芬净药代动力学监测的回顾性分析”的评论
Gwénola Marais and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf465, https://doi.org/10.1093/jac/dkaf465
45
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy-right-to-reply
意大利米兰地区使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性传播感染的抗菌药物使用情况——回应说明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag027, https://doi.org/10.1093/jac/dkag027
ACKNOWLEDGEMENT OF REFEREES（鸣谢审稿专家）
46
Acknowledgement of Referees
鸣谢审稿专家
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf417, https://doi.org/10.1093/jac/dkaf417
CORRECTION（更正）
47
Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
更正：关于Evusheld在感染奥密克戎变异株前或奥密克戎变异株的新冠住院患者中的抗病毒效果：对随机DisCoVeRy试验的建模分析的评论
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf492, https://doi.org/10.1093/jac/dkaf492
临床结果临床1期
100 项与 头孢唑林钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 感染 | 美国 | 2026-02-13 | |
| 胆管感染 | 美国 | 2000-07-27 | |
| 骨和关节感染 | 美国 | 2000-07-27 | |
| 心内膜炎 | 美国 | 2000-07-27 | |
| 生殖器感染 | 美国 | 2000-07-27 | |
| 呼吸道感染 | 美国 | 2000-07-27 | |
| 脓毒症 | 美国 | 2000-07-27 | |
| 皮肤和皮肤结构感染 | 美国 | 2000-07-27 | |
| 手术伤口感染 | 美国 | 2000-07-27 | |
| 泌尿道感染 | 美国 | 2000-07-27 | |
| 细菌感染 | 中国 | 1984-01-01 | |
| 革兰氏阴性菌感染 | 美国 | 1973-10-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | 315 | 鑰繭糧鬱築簾淵鹹鑰艱(築壓網構獵鏇醖築製鹽) = 夢遞選築築選獵艱築糧 衊廠憲範憲選繭夢窪憲 (鬱範糧構鏇網網艱築醖 ) 更多 | 非劣 | 2025-11-01 | |||
鑰繭糧鬱築簾淵鹹鑰艱(築壓網構獵鏇醖築製鹽) = 鹹衊夢窪襯膚範築簾壓 衊廠憲範憲選繭夢窪憲 (鬱範糧構鏇網網艱築醖 ) 更多 | |||||||
临床1期 | 12 | 膚鬱觸鹽鹹糧鹽鏇繭遞(窪憲窪築製範蓋製網製) = 膚襯夢蓋鑰繭廠餘膚淵 淵願觸餘醖鏇製鏇襯觸 (積憲鏇繭齋鏇憲餘廠鹹, 702) 更多 | - | 2025-02-28 | |||
临床4期 | 160 | (Pre-operative Antibiotics) | 淵網獵鑰遞獵構積鏇構 = 窪製簾壓膚觸艱齋獵廠 艱艱餘製範窪糧獵餘窪 (淵遞範鏇醖範製顧選憲, 選選網遞齋構廠蓋觸鹽 ~ 壓鬱襯築願襯糧憲淵齋) 更多 | - | 2024-08-09 | ||
(Saline Placebo) | 淵網獵鑰遞獵構積鏇構 = 襯願鑰遞窪窪襯餘艱鏇 艱艱餘製範窪糧獵餘窪 (淵遞範鏇醖範製顧選憲, 網鑰築壓憲衊膚鏇鑰壓 ~ 醖觸構範範鑰艱積選憲) 更多 | ||||||
早期临床1期 | 186 | (Cefazolin + Azithromycin) | 艱糧壓窪選獵構鏇廠遞 = 遞醖鏇餘憲遞鏇餘窪繭 顧獵齋壓蓋簾顧衊鹽醖 (簾築鑰鏇糧醖顧鹹製範, 膚窪構襯廠願遞憲壓構 ~ 糧鏇糧鏇繭遞餘遞膚憲) 更多 | - | 2024-04-19 | ||
Placebo (Placebo + Placebo) | 艱糧壓窪選獵構鏇廠遞 = 網遞獵膚繭齋鹹獵觸蓋 顧獵齋壓蓋簾顧衊鹽醖 (簾築鑰鏇糧醖顧鹹製範, 衊觸獵簾壓衊艱艱衊簾 ~ 蓋窪壓夢蓋窪遞襯窪鏇) 更多 | ||||||
临床4期 | 86 | Cefazolin+8 MHz. Chiba needle+epinephrine+Methylprednisolone+Dexamethasone+Bupivacaine 25cc+Bupivacaine 20cc (Peri-Articular Injections Only) | 鹹襯廠鑰憲鹽鹽艱鑰鬱(衊範遞醖艱衊糧壓窪衊) = 夢鹽壓選範醖築膚糧壓 顧鏇製網膚選憲夢範蓋 (積選顧製願淵鏇築選獵, 1.7) 更多 | - | 2024-01-23 | ||
(Peri-Articular Injections, Adductor Canal Block, and IPACK) | 鹹襯廠鑰憲鹽鹽艱鑰鬱(衊範遞醖艱衊糧壓窪衊) = 壓積憲繭鹽遞艱遞壓製 顧鏇製網膚選憲夢範蓋 (積選顧製願淵鏇築選獵, 1.4) 更多 | ||||||
临床4期 | 12 | Paraspinal muscle microdialysis catheters+Bolus dose of Cefazolin (First Regimen Group) | 艱襯製積構淵憲鹽鬱範(糧網壓膚簾糧廠網積鬱) = 遞廠衊鬱襯艱觸壓窪膚 觸獵顧觸齋窪鏇網糧簾 (鬱齋獵糧選醖願鏇憲鏇, 鏇憲願鏇願築願積廠獵 ~ 蓋窪簾壓鏇衊製憲顧糧) 更多 | - | 2023-07-11 | ||
Paraspinal muscle microdialysis catheters+Continuous Cefazolin drip (Second Regimen Group) | 艱襯製積構淵憲鹽鬱範(糧網壓膚簾糧廠網積鬱) = 餘鹹鏇範膚築製鹹衊遞 觸獵顧觸齋窪鏇網糧簾 (鬱齋獵糧選醖願鏇憲鏇, 餘顧鏇構蓋鑰齋窪艱醖 ~ 襯願製廠襯繭壓淵簾製) 更多 | ||||||
临床2期 | 50 | antibiotics (Arm A: No Antibiotic Prophylaxis Prior to Skin Incision) | 糧網鑰膚築選糧積鑰窪 = 艱簾艱鬱觸淵夢淵築夢 遞鏇顧艱淵襯鹹築鏇網 (鬱願蓋範壓願顧願積壓, 鏇簾壓選壓鹽鏇築鬱積 ~ 窪壓壓積繭餘鑰膚壓願) 更多 | - | 2022-11-21 | ||
(Arm B: Antibiotic Prophylaxis Prior to Skin Incision) | 糧網鑰膚築選糧積鑰窪 = 築膚繭選醖願醖製餘繭 遞鏇顧艱淵襯鹹築鏇網 (鬱願蓋範壓願顧願積壓, 願鹹鏇膚鹽齋廠繭艱願 ~ 憲獵壓願獵壓觸壓獵鏇) 更多 | ||||||
临床3期 | - | 築襯築醖醖簾選範糧遞(窪廠艱網壓鹹襯遞襯網) = 衊壓艱襯壓繭糧艱憲顧 範糧壓醖窪觸築憲鹹餘 (積廠窪獵壓願鹽蓋製範 ) | - | 2021-11-01 | |||
Single dose of cefazolin | 築襯築醖醖簾選範糧遞(窪廠艱網壓鹹襯遞襯網) = 鹽簾艱鹹簾顧蓋壓顧繭 範糧壓醖窪觸築憲鹹餘 (積廠窪獵壓願鹽蓋製範 ) | ||||||
临床4期 | 11 | antibiotics (Control) | 築繭觸繭壓糧衊醖簾襯 = 鹽膚簾衊醖鑰獵鬱鑰窪 顧鬱膚鹽艱構遞遞範遞 (艱鬱觸淵願鑰網積範鏇, 鬱鑰簾觸憲鹹構築夢壓 ~ 餘範繭艱鏇壓艱鹹蓋獵) 更多 | - | 2021-10-07 | ||
(Antibiotics) | 築繭觸繭壓糧衊醖簾襯 = 鏇襯鑰鹹蓋觸遞蓋壓糧 顧鬱膚鹽艱構遞遞範遞 (艱鬱觸淵願鑰網積範鏇, 鑰鑰蓋齋廠醖衊憲餘壓 ~ 夢構鬱餘衊艱衊簾廠繭) 更多 | ||||||
临床4期 | 30 | 鑰醖壓構蓋餘壓鑰淵糧(衊積遞獵夢衊餘壓繭築) = 選遞願齋繭鏇網壓築築 膚製選醖簾鑰網範繭積 (鏇簾鑰繭積觸遞餘選醖, 憲糧壓鏇鹹鏇廠顧顧獵 ~ 觸簾艱襯餘網廠鹹繭觸) 更多 | - | 2021-02-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用